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Zusammenfassung
In klinischen Studien werden Patienten zufällig in (üblicherweise zwei) Behand-
lungsgruppen eingeteilt. Dabei ist eine der Behandlungen in der Regel eine Neue,
bei der man die Wirksamkeit überprüfen möchte. Die andere Behandlung is meist
ein Behandlungsstandard für die vorliegende Krankheit oder ein Placebo. Nach
Studienende werden die erhobenen Daten über den Krankheitsverlauf seit Be-
handlungsbeginn analysiert, um zu klären ob und inwieweit die neue Behand-
lungsmethode besser ist. Klassische statistische Methoden für die Analyse von
randomisierten klinischen Studien nehmen an, dass der Behandlungseffekt kon-
stant, also für alle Patienten gleich, ist und – was noch wichtiger ist –, dass der
Behandlungseffekt auch für alle zukünftigen Patienten gleich sein wird. Diese An-
nahme ist besonders bei komplexen Erkrankungen und heterogenen Patientenpo-
pulationen unrealistisch. Neue statistische Methoden werden benötigt, um her-
auszufinden, ob sich Behandlungseffekte zwischen Patienten unterscheiden und,
wenn dies der Fall ist, welche Patientencharakteristiken den Behandlungseffekt
beeinflussen.
Für die Auffindung von Subgruppen, die sich hinsichtlich des Behandlungsef-
fekts unterscheiden und bei denen innerhalb der Subgruppe der Bahandlungsef-
fekt gleich ist, schlagen wir modellbasierte Bäume als geeignete statistische Me-
thode vor. Subgruppenanalysen werden im Folgenden auch als stratifizierte Medi-
zin bezeichnet. Für personalisierte Medizin, also die Schätzung von personalisierten
Behandlungseffekten, können modellbasierte Zufallswälder genutzt werden. Die
Zufallswälder liefern ein Ähnlichkeitsmass, das bestimmt, wie ähnlich sich Patien-
ten hinsichtlich des Behandlungseffekts sind. Dieses Ähnlichkeitsmass wird dann
genutzt, um in Kombination mit Modellen den Behandlungseffekt zu schätzen.
Manchmal ist bereits vor Studienbeginn bekannt, dass bestimmte Patientencha-
rakteristiken die Zielgrösse direkt beeinflussen und zwar unabhänging von der
Behandlung. In diesen Situationen ist es von Interesse, den prognostischen Effekt
dieser Patientencharakteristiken gobal zu schätzen und nicht pro Subgruppe, wie
in den oben genannten modellbasierten Bäumen. Für solche Anwendungen emp-
fehlen wir Bäume mit partiell additiven (generalisierten) linearen Modellen, auch
PALM trees – partially additive (generalised) linear model trees – genannt. In die-
sen Bäumen werden manche Modellparameter pro Subgruppe geschätzt (in der
Regel Interzept und Behandlungseffekt) und andere global (Effekte von bekann-
ten prognostischen Patientencharakteristiken).
Die PRO-ACT Datenbank enthält Daten von mehreren klinischen Studien zu Amyo-
tropher Lateralsklerose (ALS), eine komplexe neurodegenerative Krankeit für die
auf dem Markt nur ein Medikament zugelassen ist. Für dieses Medikament, ge-
nannt Riluzol oder auch Rilutek, konnte nur einen moderate Verlängerung der
Lebenserwartung nachgewiesen werden und es ist unklar, ob alle Patienten von
der Einnahme des Medikaments profitieren. Wir analysierten die PRO-ACT Daten
mit modellbasierten Bäumen und Zufallswäldern und fanden Anzeichen dafür,
dass sich die Behandlungseffekte zwischen Patienten unterscheiden. Die Analy-
sen werden im Folgeneden gezeigt, um die Methoden zu veranschaulichen.
Für alle erwähnten Methoden ist Software verfügbar. Modellbasierte Bäume und
Zufallswälder sind im R Paket partykit implementiert. Die Zielgruppe für das
partykit-Paket ist breit und daher nicht bestmöglich auf die Anwendung für stra-
tifizierte und personalisierte Medizin abgestimmt. Daher bieten wir auch ein Zu-
satzpaket mit dem Namen model4you an, das leicht zu bedienen ist und interpre-
tierbare Graphiken erzeugt. PALM trees sind im palmtree-Paket implementiert.
Abstract
In randomised clinical trials patients are randomly assigned to a new treatment
of interest or a control, e.g. the standard of care or a placebo. At the end of the
study, data about the course of the disease of the patients is analysed to answer the
question whether the new treatment is better than the control. Established statisti-
cal procedures for the analysis of primary endpoints in randomised clinical trials
assume that there is a universal, i.e. constant, treatment effect that applies to all
patients in the trial and - even more importantly - to all future patients potentially
to be treated with the new treatment under consideration. For complex diseases
or heterogeneous patient populations this assumption may be incorrect and novel
statistical methods are needed to discover if treatment effects differ across patients,
and if so, which patient characteristics influence treatment effects.
We propose model-based trees as a method for stratified medicine – i.e. for the dis-
covery of patient subgroups, where within subgroups the treatment effects are the
same and between subgroups treatment effects differ. Using ensembles of model-
based trees (model-based forests) we can detect similarities between patients in
terms of treatment effects and use the similarity measure to estimate personalised
treatment effects (personalised medicine).
Sometimes patient characteristics are known to have a direct effect on the primary
outcome, irrespective of treatment. In these situations it may be relevant to esti-
mate global effects for these prognostic factors. As this is not possible in regular
model-based trees, we propose partially additive (generalised) linear model trees
(PALM trees) as a variation of classical model-based trees where some effect es-
timates are stratified (usually intercept and treatment effect) and some are global
(effects of known prognostic factors).
The PRO-ACT database contains data from several clinical trials about amyotrophic
lateral sclerosis (ALS), which is a complex neurodegenerative disease for which
only one drug, Riluzole, is available on the market. The drug has been shown
to be only moderately effective and it is unclear if all patients benefit from it.
We analysed the PRO-ACT data using model-based trees and forests and found
evidence that treatment effects vary across patients. We use the analysis of the
PRO-ACT data to guide the reader through the different methods.
Open source software for all proposed methods is available. The partykit pack-
age implements basic model-based trees and random forests in R. The function-
ality in the partykit package is aimed at a broad audience. To make it easy for
users interested in stratified and personalised medicine, we offer an add-on pack-
age called model4you, which focuses on user friendliness and interpretability of
the results. PALM trees are implemented in package palmtree.
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Introduction
This thesis covers model-based trees and forests for the estimation of stratified
and personalised treatment effects. It explains why model-based recursive parti-
tioning – although not exclusively designed for it – is so useful for stratified and
personalised medicine and describes how it works.
This introduction unfolds as follows: Section 1 defines the terms stratified and
personalised medicine and documents the importance of the topic and respective
statistical methods. Section 2 introduces relevant statistical methods. Parametric
models are discussed first (see Section 2.1) as they have traditionally been used for
the estimation of treatment effects and form the basis of model-based recursive
partitioning. Then Section 2.2 gives an introduction into model-based recursive
partitioning including model-based trees, PALM trees and model-based forests.
The usage is illustrated on data from ALS patients. Section 3 gives a brief overview
of the four papers forming the output of this Ph.D. project. My work has already
sparked some interest in the academic as well as in the pharmaceutical community,
which is documented in Section 4.
1 Stratified and personalised medicine
Personalised medicine (also called precision medicine) has been a buzzword in recent
years, especially following Barack Obama’s 2015 speech introducing the US preci-
sion medicine initiative1 , where he said:
“And that’s why we’re here today. Because something called precision
medicine – in some cases, people call it personalized medicine – gives us one
of the greatest opportunities for new medical breakthroughs that we have ever
seen. Doctors have always recognized that every patient is unique, and doctors
have always tried to tailor their treatments as best they can to individuals.
You can match a blood transfusion to a blood type. That was an important
discovery. What if matching a cancer cure to our genetic code was just as
easy, just as standard? What if figuring out the right dose of medicine was as
simple as taking our temperature?”
Obama speaks about “delivering the right treatments [. . .] to the right person”,
but at the same time he speaks about accurately diagnosing diseases. This shows
that the term personalised medicine is not clearly defined (see also Schleidgen et al.,
2013). In the context of genomics or rare diseases it can be understood as the
accurate identification of a disease. In other contexts it is understood as the iden-
tification of the optimal treatment for each patient or, as in this thesis, the estima-
tion of personalised treatment effects. Note that patient characteristics influencing
the treatment effect might as well signal that patients are suffering from different
sub-diseases. For example, a gene mutation could lead to a certain sub-disease
that should be treated differently. Identifying the sub-disease may then be a side
product of estimating personalised treatment effects, but is not the original aim.
The terms personalised medicine and stratified medicine are often used synonymously.
In this work I differentiate between stratified medicine, where subgroup-wise
treatment effects are estimated and the focus lies on identifying the patient char-
acteristics defining the subgroups, and personalised medicine, where we go a step
further and estimate a treatment effect for each individual. Treatment effects may
well be homogeneous among a study population and statistical methods for per-
sonalised and stratified medicine must not only be able to identify patient charac-
terstics interacting with the treatment but must also be able to identify when there
is no heterogeneity.
The aim of my work is to detect patient characteristics that influence the treatment
effect. In the medical literature these patient characteristics are commonly referred
to as predictive factors (see e.g. Italiano, 2011). Patient characteristics affecting the
outcome or progression, called prognostic factors, are of secondary interest, but
are also retrieved in model-based recursive partitioning, giving a holistic view on
health of patients. For a visual reminder of the difference between predictive and
prognostic factor see Figure 1.
1https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/remarks-
president-precision-medicine
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Figure 1: Definition of prognostic and predictive factors.
The regulatory agencies EMA and FDA are recognising that stratified and person-
alised medicine is an important topic for drug development (see reports US Food
and Drug Administration, 2013; European Medicines Agency, 2014) and the topic
is currently frequently discussed in academia (e.g. Weisberg, 2015), pharmaceuti-
cal industry (Das, 2017) and even the media (e.g. New York Times Editorial Board,
2015). The standard way of analysing clinical trials, however, is estimating average
treatment effects, i.e. one treatment effect per study population. Since their rise
in popularity after the first randomised controlled trial conducted in 1946, ran-
domised clinical trials have helped medical researchers to develop and evaluate
new treatments for many diseases. Hence randomised clinical trials and average
treatment effects are rightfully popular. In recent years, drug and treatment de-
velopment has become more difficult, since treatments for less complex diseases
are already known (Weisberg, 2015). Developing treatments for complex diseases
with unknown underlying biological processes or unknown subcategories is ex-
tremely difficult. One treatment may work for a patient with disease subcategory
A but not for a patient with disease subcategory B. The finding that trastuzumab
should only be used for breast cancer patients with HER-2 protein overexpression
(Slamon et al., 2001; Frueh and Gurwitz, 2004) is a famous example. For diseases
where patients react to the same treatment in different ways, medical research
needs statistical methods that can detect and estimate heterogeneous treatment
effects. These exploratory methods can then influence hypothesis generation and
thus aid planning of more specific and informed clinical trials.
The articles in this thesis each deal with stratified and/or personalised medicine
and focus on statistical methods that detect patient characteristics influencing the
treatment effect and then estimate stratified or personalised treatment effects, so
that future clinical trials can be designed using well informed hypotheses, gener-
ated with the help of statistically sound data driven methods.
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2 Statistical methods for stratified and personalised
medicine
This section describes statistical methods used to analyse clinical trials. Parametric
and semi-parametric models are the standard for estimating average treatment
effects and these same models can be used to partition the data using model-based
recursive partitioning to retrieve stratified or personalised treatment effects.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that leads to
shrinking of muscles. Patients suffer from speaking and swallowing problems and,
ultimately, breathing impairment. ALS patients have a low survival expectancy
and the only approved drug against ALS – Riluzole – has been shown to prolong
life expectancy by merely 2 months (European Medicines Agency, 2012). This
gives a first impression on how complex this disease is. Two of the articles in this
thesis analyse data from ALS patients. The data are a collection of clinical trials
about ALS (Pooled Resource Open–Access Clinical Trials database, Atassi et al.,
2014) and next to treatment information also contain information about baseline
patient characteristics. The question is, which patient characteristics lead to dif-
ferences in Riluzole treatment effects and what are the treatment effects for given
patients. In the following I will demonstrate the methods by analysing the Rilu-
zole effect on the survival of ALS patients.
2.1 Models for the estimation of treatment effects
Parametric models such as linear models, generalised linear models or accelerated
failure time models and the semiparametric Cox model are the most commonly
used models for the estimation of treatment effects in clinical trials. The model,
M((Y,X), ϑ), (1)
to be used for this primary analysis is generally defined in the study protocol
including the primary endpoint Y, covariates X and parameters ϑ. The covariates
in this model always contain the treatment indicator
Xtreatment =
{
1 if patient receives the new treatment
0 else.
(2)
Possibly further relevant covariates can be included. In the simplest case the pa-
rameters ϑ include an intercept (or baseline hazard) and a treatment effect. To
- 4 -
estimate 2.5 % 97.5 %
α1 6.7070 6.6438 6.7702
β 0.1073 0.0314 0.1832
log(α2) −0.5833 −0.6365 −0.5302
Table 1: Parameter estimates including confidence intervals of overall Riluzole effect Weibull
model in the PRO-ACT data.
estimate the parameters, the objective function Ψ – e.g. the negative log-likelihood
– is minimised or equivalently the score equation
n
∑
i=1
ψ((y, x)i, ϑ) = 0 (3)
is solved. The score contributions ψ((y, x)i, ϑ) – with i = 1, . . . , n and n = number
of patients in the trial – are the derivatives of the contributions to the objective
function (e.g. log-likelihood contributions).
To estimate the Riluzole effect on the survival of ALS patients, we use a Weibull
model. This means, that the parameter vector ϑ contains three parameters: two
parameters defining the baseline hazard, which we call α1 (intercept) and α2 (scale
parameter), and the treatment effect parameter, β. Weibull models are estimated
via maximum-likelihood estimation, wich means that our objective function is the
negative log-likelihood. The estimated parameters of this model are shown in
Table 1 and the estimated survivor curves for the two treatment groups are shown
in Figure 2. Both suggest that Riluzole leads to a slightly prolonged survival. The
estimated difference in median survival between the two treatment groups is 75.5
days (i.e. about 2.5 months).
Secondary analyses estimating the treatment effect in different patient subgroups
are usually conducted using the same model but using different subsets of the
data and these subsets are commonly decided upon by experts. If, for example,
the experts think that the treatment may work differently in old and young pa-
tients, they decide on a certain age defining the cutpoint where everyone below
this age is assigned to the young patient group and vice versa. This procedure
may be problematic for several reasons: (1) The expert might not know about
certain patient characteristics interacting with the treatment effect; (2) higher or-
der interactions might play a role, i.e. interactions between more than one patient
characteristic and the treatment; (3) there might be a better cutpoint than the one
defined by the expert or the interaction might be a smooth function instead of
a step function with a certain cutpoint. All of these problems can be addressed
- 5 -
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Figure 2: Survivor functions of ALS patients in the two treatment groups estimated by a Weibull
model usign the PRO-ACT data.
by using a data driven method such as model-based trees and forests instead of
expert knowledge.
2.2 Model-based recursive partitioning for the estimation of stratified and
personalised treatment effects
Trees are designed to detect even high order interactions in a data driven way.
This is why, even though they are not classically used for the analysis of clinical
trials, they have been proposed by various authors as good methods for stratified
medicine (see e.g. Dusseldorp and Van Mechelen, 2013; Foster et al., 2011; Negassa
et al., 2005). Trees recursively split observations into subgroups where observa-
tions within a subgroup are similar and between subgroups different. Usually the
similarity is defined in terms of the response. The splits are implemented based
on split variables, which, in this work, are the patient characteristics. Trees can be
visualised in an easy to understand and interpretable fashion. A random forest
consists of an ensemble of trees. The trees in the forest differ from each other,
because each tree is based on a subsample or bootstrap sample of the original
data and for each split only a subset of split variables is made available. The trees
in the forest have an even higher variablity since they are usually grown larger
(deeper) than single trees. By introducing variation in the single trees and then
averaging or synthesising the results, predictive performance of random forests is
often better that of single trees (Breiman, 2001; Hastie et al., 2009). However, in
comparison to trees, random forest are not interpretable.
Classical trees and random forests do not allow the user to focus on interactions
with the treatment. For this, a combination of models and trees as in model-based
- 6 -
recursive partitioning is useful. This combination provides the best of both the
tree world and the model world: Having models that are accepted and understood
in the medical community and at the same time being able to find treatment ×
subgroup interactions in a data driven way.
The general idea of model-based recursive partitioning is to partition the data
based on instabilities in the model parameters. In the application for stratified and
personalised medicine, we are especially interested in instabilities in the treatment
effect, but commonly model-based recursive partitioning also finds instabilities in
the intercept. The first leads to the detection of predictive factors, the latter to the
detection of prognostic factors. The first step of the algorithm is to compute the
model for all n patients of the study sample as in Equation (3). Parameters of this
model are considered unstable, if the corresponding scores (partial derivative of
the contributions to the objective function) do not fluctuate randomly around zero
but are correlated to at least one patient characteristic. The intuition for this is
that the scores are residuals and we aim to estimate the optimal model. Scores
that are correlated with patient characteristics indicate that certain information
was not taken into account. The lowest p-value in tests of independence between
the scores and each patient characteristic determines the patient characteristic in
which to implement the split. The actual split point can either be found using
again an independence test or by maximising the sum of objective functions of the
models in the resulting subgroups. The algorithm recursively proceeds with the
model estimation, testing and splitting in each subgroup. It stops when either no
p-value is smaller than a predefined significance level (Bonferroni correction can
be used here to adjust for multiple testing) or another stopping criterion – such as
minimum number of observations in the subgroups – is fulfilled.
Model-based trees use the above algorithm and estimate one model per sub-
group to obtain the stratified treatment effects. This is equivalent to solving the
weighted score equation,
n
∑
i=1
wigψ((y, x)i, ϑg) = 0, (4)
with wig =
{
1 if patient i is in subgroup g
0 else.
By estimating the parameters per subgroup, where subgroups are defined by com-
binations of (binary) rules based on patient characteristics, we estimate parameter
× patient characteristics interactions that are step functions depending on patient
- 7 -
characteristics, i.e.
ϑ(zi) =

ϑ1 if patient i with patient characteristics zi is in subgroup 1
...
ϑg if patient i with patient characteristics zi is in subgroup g.
(5)
By stopping based on (Bonferroni corrected) p-values and controlling the probabil-
ity of incorrectly rejecting the null hypothesis of no parameter instability, the algo-
rithm ensures that splits are rarely implemented, if the the true model parameters
are the same for all patients. In this case, all patients are in the same “subgroup”
and Equation (4) equals Equation (3). Model-based trees work well when clear
treatment × subgroup interactions exist and effects of potential unknown prog-
nostic factors can be approximated well by step functions. If prognostic factors are
known, they can be included in the model. In this case a variation of model-based
trees called partially additive linear model (PALM) trees can be used. PALM trees
allow for prognostic factors to be included in the model in a way that their effect
estimates are the same across all subgroups. So instead of a linear predictor x>i ϑg
with all parameters depending on the tree structure, the linear predictor is
x>i
(
θg
γ
)
(6)
with parameters θg (e.g. intercept and treatment effect) depending on the tree
structure and parameters γ (effects of known prognostic factors) being fixed across
all patients.
Figure 3 shows the model-based tree for the ALS data. Note that for this tree one of
the stopping criteria was to have maximally four subgroups. The figure shows the
split variables forming the subgroups, including the p-value of the independence
test in the ovals. The numbers on the lines specify the split point. The tree defines
four subgroups: patients who are of age 43 or younger, patients who are between
43 and 55.7 years old, patients who are older than 55.7 and for whom the time
between disease onset and treatment start is 757 days or less, and patients who
are older than 55.7 and for whom the time between disease onset and treatment
start is more than 757 days. For each subgroup the estimated parameters and
“confidence intervals”, the number of observations (n) and the survivor curves in
both treatment groups are given. The interpretation of confidence intervals here is
unclear due to the variable and split point selection which is done prior to model
estimation (for a discussion of the problem see Leeb and Pötscher, 2005). We
suggest to not use them for inference but as a measure of variability. The subgroup
with patients of age 43 or younger shows very similar survivor curves for both
treatment groups, which suggests that Riluzole has no effect on the survival of
young patients. A similar picture is shown for the subgroup of patients who are
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over 55.7 years old and for whom the time between disease onset and treatment
start was longer than 757 days. The other two subgroups show a higher treatment
effect than the overall treatment effect (see Table 1).
Patients with slow disease progression were mostly included late in the studies,
which means that the time between disease onset and treatment start is a surrogate
for the speed of disease progression and is thus a known prognostic factor also
for the survival of patients. In this case it could be a good idea to include the time
between disease onset and treatment start as a covariate in the model and fixing
it across subgroups, which corresponds to the idea of PALM trees (the current
implementation of the PALM tree algorithm is for generalised linear models and
linear models only).
Model-based forests, like classical random forests, compute an ensemble of rel-
atively deep trees. The usage of model-based forests, however, differs from the
classical forests: Model-based forests are used to estimate the similarity of pa-
tients in terms of model parameters. In model-based trees, patients are assigned
to the same subgroup if they have the same (or similar) model parameters. In
this sense, the similarity between patients is one if they are in the same subgroup
and zero if they are in different subgroups. A weighted model with the binary
similarity measure as model weights is estimated for each subgroup g as shown
in Equation (4). With model-based forests we can obtain a similarity measure that
ranges between zero and the number of trees. The similarity between two patients
is then the number of times they are assigned to the same subgroup in the given
trees. In accordance with the stratified models, the personalised model for a new
patient k is estimated by solving
n
∑
i=1
wikψ((y, x)i, ϑk) = 0 (7)
with wik = number of times patients i and k are in the same subgroup. If pa-
tient k is not a new patient but was in the data set used to compute the forest,
the weights should be computed out-of-bag to avoid including information from
patient k in the model of patient k. Using the similarity weights obtained by
model-based forests allow for flexible estimation of personalised models. This
can lead to complex treatment × patient characteristics interactions – and more
general a complex form of ϑ(z) – in contrast to model-based trees where the inter-
actions are always step functions (see Equation (5)). Since trees in random forests
are grown larger than in single trees, we need to implement a possibility to detect
if the personalised models are better than the base model (a single model estimat-
ing the average treatment effect). The difference in objective functions from the
personalised models and the global model (estimated as in Equation (3)) gives an
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Figure 4: Illustration: test whether personalised models improve upon base model. If the true
difference is high in comparison to the null distribution (density curve shown), we
assume that the personalised models fit the data better than the base model.
idea of improvement. Using parametric bootstrap samples from the global model
and computing again the difference in objective functions gives the distribution
of differences under the null hypothesis “the base model is the correct model”
(see density curve in Figure 4 as an example), which allows us to perform a sig-
nificance test. If the difference in the original data is high in comparison to the
differences under the null hypothesis (e.g. value corresponding to the blue line in
Figure 4) the personalised models are an improvement in comparison to the base
model.
For the ALS data the test suggests that the personalised models are better than the
base model shown in Table 1 and Figure 2. Figure 5 shows the distribution under
the null hypothesis of no difference in log-likelihood between the base model and
the personalised models on the left hand side. On the right hand side the actual
difference is added (denoted by H1). The difference in log-likelihoods between
the personalised models obtained trough the forest and the base model is much
larger than any of the differences under the null hypothesis. Figure 6 shows the
dependence plots for the personalised models computed. Different patient char-
acteristics are plotted on the x-axis. The difference in estimated median survival
between taking or not taking Riluzole for every patient is plotted on the y-axis. In
normal linear models the personalised treatment effect could be plotted directly
on the y-axis, as it can be interpreted as the expected improvement (or worsening)
by taking the treatment instead of the control. For the Weibull model the treatment
effect is the hazard ratio, which is hard to interpret – especially in comparison to
other hazard ratios with different baseline hazards – which is why we chose the
difference in median survival instead. The difference in median survival increases
with increasing age up to 55 years and then goes down and flattens. Weak patients
have a greater variability in treatment efficacy than patients who are not weak at
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Figure 5: Test whether personalised Weibull models improve upon base model for the PRO-
ACT database. Density curve shows the distribution under the null hypothesis. The
two plots show the same on different scales (see changes in x-axis).
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els for ALS patients in the PRO-ACT database.
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baseline.
Summary: In this section we discussed conventional methods for the analysis of
randomised clinical trials as well as new methods for stratified and personalised
medicine. The estimates obtained by solving Equations (3), (4), and (7) give the
overall, stratified, and personalised treatment effect respectively, i.e. the first (ϑˆ)
applies to all patients, the second (ϑˆg) to a subgroup g, and the last (ϑˆk) to a
single patient k. Model-based recursive partitioning methods can be used for
exploratory analysis of clinical trials. The intended use of these methods is to
identify whether treatment effect heterogeneity exists in the given patient population
and then to generate hypotheses based on potential findings. These hypotheses can
then be used to inform new clinical trials.
Software for computing model-based trees, model-based forests and PALM trees
is available in open source R packages. The partykit package provides all base
functionalities. Package model4you provides a user-friendly interface for the ap-
plication of model-based trees and forests for stratified and personalised medicine
including visualisation functionality for easy interpretation and communication
of models and results. PALM trees are available in the palmtree package. De-
velopment versions of all packages are available on the R development platform
R-Forge2. The partykit package is also available on the Comprehensive R Archive
Network (CRAN)3.
3 Thesis summary
This thesis consists of four papers. Each paper deals with different aspects of
model-based recursive partitioning for stratified or personalised medicine. The
first paper introduces model-based trees as a method for stratified medicine; the
second paper describes model-based forests and the computation of personalised
models; the third paper introduces the PALM tree algorithm; The fourth paper
describes the R package model4you, which implements model-based trees, model-
based forests and personalised models in a user-friendly way. The contents are
summarised below.
2https://r-forge.r-project.org/projects/partykit/
3https://CRAN.R-project.org/package=partykit
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Paper I: Model-Based Recursive Partitioning for Subgroup Analyses
by Heidi Seibold, Achim Zeileis, and Torsten Hothorn
This article describes the basics of how model-based recursive partitioning can be
used for stratified medicine. Model-based trees are used to analyse data collected
in several clinical trials about Amyotrophic Lateral Sclerosis (ALS) and the effect
of the drug Riluzole (the only approved drug against ALS) on survival and health
of patients. The models used within the model-based trees are the following:
Survival is analysed both by partitioning a Weibull model as well as a Cox model.
Health is measured by a ten item sum score, the ALS Functional Rating Scale
(ALSFRS), and analysed by partitioning a Gaussian model. Since not only the
sum score but also each item is of interest, ten proportional odds models, one
model per item, are combined in a tree by combining the score matrices of all ten
models. The paper shows that model-based trees are able to identify predictive
and prognostic factors and that the corresponding visualisations allow for easy
interpretation, which makes them a good tool to communicate the results.
At the Workshop on Classification and Regression Trees4 (March 2014), sponsored by
the Institute for Mathematical Sciences of the National University of Singapore
my supervisors, Torsten Hothorn and Achim Zeileis, learned about the need for
methods for stratified medicine and realised that model-based trees are good for
this use-case. This sparked the idea for my Ph.D. project and lead to this first
paper. It was published in 2016 in the International Journal of Biostatistics.
Paper II: Individual treatment effect prediction for amyotrophic lateral
sclerosis patients
by Heidi Seibold, Achim Zeileis, and Torsten Hothorn
This article explains how model-based forests can be used to estimate similarity of
patients in terms of model parameters, e.g. intercept (or baseline hazard) and treat-
ment effect, and, with the help of this similarity measure, estimate personalised
models. Again the survival and health of ALS patients is analysed. Treatment of
interest is again Riluzole (versus no treatment). The personalised models show
that treatment heterogeneity is present and visualising personalised treatment ef-
fects shows interesting patterns for relevant patient characteristics. We investi-
gated the performance of the method in simulations and showed that it works
well even in scenarios with complicated treatment × covariate interactions.
The paper is published in the Journal Statistical Methods in Medical Research.
4http://www2.ims.nus.edu.sg/Programs/014swclass
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Paper III: Generalised Linear Model Trees with Global Additive Effects
by Heidi Seibold, Torsten Hothorn, and Achim Zeileis
In this article we propose partially additive linear model (PALM) trees as a way
to gain all benefits from model-based trees and additionally allowing for covariate
effects that are the same for all subgroups. An extensive simulation study shows
the performance of PALM trees in comparison to competitors including classical
model-based trees. PALM trees perform well in scenarios with global prognostic
factors and, at the same time, keep the ability of model-based trees to stick to the
global model and do not split in case of no subgroups. We applied the method
in a setting where performance of students in a mathematics exam is of interest
and students receive one of two slightly different exams. Knowledge about their
performance throughout the semester is known and an obvious prognostic factor
that can be included in the model.
This project was inspired by Sies and Van Mechelen (2017). They compare different
methods for the detection of optimal treatment regimes, including model-based
trees, in a simulation study. The way they simulated data suggested that there
are known prognostic factors that have a linear effect on the outcome of interest.
Beyond the grant for my Ph.D. project (205321_163456) the Swiss National Science
Foundation supported this project with a mobility grant (205321_163456/2) which
allowed me to visit Achim Zeileis’ group at the University of Innsbruck. The
article is available on the pre-print server arXiv5 and waiting for the second round
of reviews at the Journal Advances in Data Analysis and Classification.
Paper IV: model4you: An R package for personalised treatment effect
estimation
by Heidi Seibold, Achim Zeileis, and Torsten Hothorn
The final article introduces the R package model4you6 which implements the method-
ology of papers I and II. The package focuses on ease of use and interpretability.
It provides a very simple interface, where users compute the overall model (base
model) and insert it in the pmtree or pmforest function to compute model-based
trees and forests respectively. The pmodel function can be used to compute per-
sonalised models from the model-based forest results. It is important that the
software is open source, easy to use and produces high quality visualisations, so
that a broad audience can use our methods. The manuscript describes a simple
use case and gives an overview of the software information.
5https://arxiv.org/abs/1612.07498
6The R package model4you is currently available on https://r-forge.r-project.org/projects/
partykit/
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I will submit the article to the Journal of Open Research Software as soon as the
package is published on the Comprehensive R Archive Network (CRAN).
4 Impact and outreach
Although only two of my four papers have been published, my work has already
started to get attention and make an impact.
Model-based trees for stratified medicine as described in my first article were used
by Sies and Van Mechelen (2017) in a simulation study, comparing tree-methods
that are able to detect optimal treatment rules. The only competitive opponent
was a method by Zhang et al. (2012), which can not estimate treatment effects as
of itself, but only create treatment rules.
Beyond classical subgroup analysis, where the focus is on estimating treatment
effects for a given treatment dose, subgroup analysis for dose-response models
is one task in drug development. In a collaboration with Marius Thomas and
Björn Bornkamp, statisticians at the pharmaceutical company Novartis, we imple-
mented model-based trees for dose-response models and studied their behaviour
in a simulation study and in a phase II clinical trial assessing the efficacy of a new
treatment for an inflammatory disease. The results suggest that model-based trees
can be used for dose-response subgroup analysis. The paper with the title “Sub-
group identification in dose-finding trials via model-based recursive partitioning”
was accepted for pulishing in the journal Statistics in Medicine.
Yi-Ping Lin, research associate at the Koo Foundation Sun Yat-Sen Cancer Hospital
in Taiwan, uses model-based trees and forests to analyse breast cancer data col-
lected at the hospital since 1990. The aim is to provide a website with recommen-
dations for treatment of breast cancer patients based on patient characteristics.
For my second paper “Individual treatment effect prediction for amyotrophic lat-
eral sclerosis patients”, published in the journal Statistical Methods in Medical Re-
search I received the Arthur-Linder Prize7, which is awarded to a young member
of the Austro-Swiss Region of the International Biometric Society (RoeS) every second
year. The prize is awarded at the for an excellent research paper in the field of
biometrics. I received the prize in 2017 at the Joint Conference on Biometrics & Bio-
pharmaceutical Statistics8 in Vienna.
In November 2016 I visited the German Cancer Research Centre following an in-
vitation by Axel Benner. His group is working on high dimensional data and they
7https://www.ibs-roes.org/home-en/arthur-linder-prize
8http://cenisbs2017.org
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are interested in using our methods in this context. We are currently collaborating
on a project analysing the personalised treatment effects of patients suffering from
acute myeloid leukemia (AML). Patient characterstics in this project are 19, 656
gene expressions. The high dimensionality of the split variables demands a new
infrastructure for the computation of personalised models and good computa-
tional performance. Julia Krzykalla is currently starting her Ph.D. project at the
German Cancer Research Centre, extending on my research. Her tentative project
title is: “Modelling strategies for the identification of prognostic and predictive
factors in competing risks and multi-state models”.
Simon Foster, psychologist at the University of Zurich, studies the treatment re-
sponse of adolescents suffering from depression. Several treatments or treatment
combinations are available. In a collaboration with Lynette Tay, Meichun Mohler-
Kuo and Torsten Hothorn, we estimated personalised treatment responses for
the Treatment for Adolescents With Depression Study (TADS) of all two-way treat-
ment comparisons: cognitive-behavioural therapy versus Fluoxetine (an antide-
pressant drug, which inhibits selective serotonin reuptake); cognitive-behavioural
therapy versus the combination of cognitive-behavioural therapy and Fluoxetine;
and Fluoxetine versus the combination of cognitive-behavioural therapy and Flu-
oxetine. The results show that the combination of cognitive-behavioural therapy
with Fluoxetine was consistently superior to either therapy alone across patients
and should be the preferred treatment.
In November 2017 I was invited to present a the Biogen Symposium on Statisti-
cal Methods in Multiple Sclerosis at the Biogen Corporate Offices in Cambridge,
Massachusetts. Biogen is interested in a collaboration to apply our methods for
multiple sclerosis research.
Throughout my Ph.D. I had several opportunities to present this work at interna-
tional conferences including the useR! 2016 conference in Stanford (USA) and the
CEN ISBS conference 2017 in Vienna (Austria). In 2017 I was an invited speaker
at the Statistical Computing workshop in Günzburg (Germany). Slides for my pre-
sentations are available on GitLab9.
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Abstract: The identification of patient subgroups with differential treatment effects is the first step towards
individualised treatments. A current draft guideline by the EMA discusses potentials and problems in
subgroup analyses and formulated challenges to the development of appropriate statistical procedures
for the data-driven identification of patient subgroups. We introduce model-based recursive partitioning as
a procedure for the automated detection of patient subgroups that are identifiable by predictive factors. The
method starts with a model for the overall treatment effect as defined for the primary analysis in the study
protocol and uses measures for detecting parameter instabilities in this treatment effect. The procedure
produces a segmented model with differential treatment parameters corresponding to each patient sub-
group. The subgroups are linked to predictive factors by means of a decision tree. The method is applied to
the search for subgroups of patients suffering from amyotrophic lateral sclerosis that differ with respect to
their Riluzole treatment effect, the only currently approved drug for this disease.
Keywords: subgroup analysis, personalized medicine, treatment efficacy, permutation test, amyotrophic
lateral sclerosis
1 Introduction
With the rise of personalised medicine, the search for individual treatments poses challenges to the
development of appropriate statistical methods. Subgroup analyses following a traditional statistical
assessment of an overall treatment effect of a new therapy aim at identifying three groups of patients: (1)
those who benefit from the new therapy, (2) those who do not benefit, and (3) those whose clinical outcome
under the new therapy is worse than under alternative therapies. Such post-hoc subgroup analyses
potentially lead to better benefit-risk decisions and treatment recommendations but are subject to all
kind of biases and can hardly be performed under full statistical error control. Therefore, the European
Medicines Agency (EMA) recently published a draft of a guideline for the investigation of subgroups in
confirmatory clinical trials [1] that discusses potential areas of application, necessity, pitfalls, and good
practice in subgroup analyses. In the guideline draft, three scenarios in which exploratory investigation of
subgroups is of special interest were identified:
Scenario 1: “The clinical data presented are overall statistically persuasive with therapeutic efficacy
demonstrated globally. It is of interest to verify that the conclusions of therapeutic efficacy (and safety)
apply consistently across subgroups of the clinical trial population.”
Scenario 2: “The clinical data presented are overall statistically persuasive but with therapeutic efficacy or
benefit/risk which is borderline or unconvincing and it is of interest to identify post-hoc a subgroup,
where efficacy and risk-benefit is convincing.”
Scenario 3: “The clinical data presented fail to establish statistically persuasive evidence but there is
interest in identifying a subgroup, where a relevant treatment effect and compelling evidence of a
favourable risk-benefit profile can be assessed.”
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Especially in trials with highly heterogeneous study populations, subgroup analyses can help to reduce the
variability of the estimated overall treatment effect by splitting the study population into more homoge-
neous subgroups.
Information about the individual treatment effect might be available from cross-over trials or from counter-
factual analyses of parallel-group designs [2, 3]. These individual effects can then be linked to potentially
predictive variables. In the absence of such information, most importantly in the case of parallel-group designs
studied here, subgroup analyses can be seen as the search for or specification of treatment × covariate
interactions and we proceed along this path. A covariate measures a patient characteristic that potentially
explains the patient’s individual treatment effect. In the commonly applied models with linear predictors, such
as the linear, generalised linear or linear transformation models, the specification of higher-order interaction
terms and especially the subsequent inference are known to be burdensome. For non-categorical covariates, it is
a priori unclear how one can derive a subgroup from a significant treatment × covariate interaction.
Automated interaction detection [4], today known as recursive partitioning methods or simply “trees”, was
suggested as an interaction search procedure more than 50 years ago, and has had a very active development
community ever since. Although the application of trees for subgroup identification seems to be straightfor-
ward, no generally applicable method is available [5]. The main technical problem is that classical trees were
developed for identifying higher-order covariate interactions but additional work is required to restrict inter-
actions to treatment × covariate interactions. Due to the non-parametric nature of most tree models, blending
trees with the linear models typically used to describe the treatment effect is challenging.
While setting up such automated procedures for subgroup identification, one has to bear in mind that the
impact of a covariate on the endpoint can be prognostic, predictive, or both. Prognostic factors have a direct
impact on the endpoint, independent of the treatment applied. This corresponds to a main effect. A predictive
factor explains a differential treatment effect, i.e. a treatment × covariate interaction term. Both the main and
the treatment interaction terms are important for factors that are prognostic and predictive at the same time [6].
In our analysis, we aimed at detecting subgroups of patients suffering from amyotrophic lateral
sclerosis (ALS) in which the subgroups differ in the effect of treatment with Riluzole, the only approved
drug for ALS treatment today. The two endpoints of interest are a functional endpoint assessing the
patient’s ability to handle daily life and the overall survival time. We estimated the overall treatment effect
of Riluzole using four different base models; the choice of the model depended on the measurement scale of
the endpoint. A normal generalised linear model (GLM) with log-link was used for the sum-score of the
functional endpoint, and item-specific proportional odds models were used for the decomposed score. For
the right-censored survival times, we used a parametric Weibull model and a semiparametric Cox model.
Our aim was to partition these linear models with respect to the treatment effect parameter and to develop a
segmented model that includes treatment × covariate interactions that describe the relevant subgroups.
We applied model-based recursive partitioning [7] to the functional and survival models describing the
effect of Riluzole on ALS patients in order to obtain subgroups with a differential treatment effect. The main
advantage of embedding our subgroup analysis into this general framework of model partitioning is that
one can partition the base model used for analysing the overall treatment effect, regardless of the
measurement scale of the endpoint. The method allows us to focus attention on predictive factors, while
other terms, such as the effects of strata or nuisance parameters, can be held fixed.
Section 2 introduces the general framework for subgroup identification and compares the new proce-
dure to methods published previously in the light of this general theoretical framework. In Section 3, we
present results of our subgroup analysis of Riluzole treatment of ALS patients and discuss the patient
subgroups and corresponding differential treatment effects found.
2 Model-based recursive partitioning for subgroup identification
Subgroup analyses require the definition of a parameter describing the treatment effect. In clinical trials,
this parameter is typically already contained in the model that was defined in the study protocol for the
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analysis of the primary endpoint. The treatment effect was estimated in the primary analysis under the
assumption that the corresponding parameter is universally applicable to all patients. In the presence of
subgroups, this assumption does not hold and these patient subgroups differ in their treatment effect. If
we assume that the different treatment effects can be understood as a function of patient characteristics,
the patient subgroups can be identified by estimating this treatment effect function. Model-based
recursive partitioning can be employed as a procedure for the estimation of such a treatment effect
function and the identification of the corresponding patient subgroups. The name of the procedure comes
from the nature of the algorithm that recursively partitions the initial model used for the analysis of the
primary endpoint.
2.1 Model and algorithm
We started with a modelmððY,XÞ, ϑÞ that describes the conditional distribution of the primary endpoint Y
(or certain characteristics of this distribution) as a function of the treatment arm and potentially further
covariates (both contained in X) through parameters ϑ as defined in the study protocol. The parameter
vector ϑ= ðα, β, γ, σÞ` typically contains one or more intercept parameters α, one or more treatment effect
parameters β, other model parameters γ, e.g. effects of covariates, and potential nuisance parameters σ, e.g.
the error variance in a linear model. The estimator is defined as the minimizer of an objective function Ψ,
which usually is the negative log-likelihood:
ϑ^= argmin
ϑ
XN
i= 1
Ψððy, xÞi, ϑÞ. (1)
Estimating ϑ is equivalent to solving the score equation
XN
i= 1
∂Ψððy,x Þi, ϑÞ
∂ϑ
=
XN
i= 1
ψððy,xÞi, ϑÞ=0, (2)
where ψ is the score function, i.e. the gradient of the objective function Ψ with respect to ϑ. The model
framework is more general than the log-likelihood framework because Ψ is not necessarily a negative log-
likelihood function.
In the presence of patient subgroups that differ in their treatment effect β, an estimate β^ obtained for all
patients i= 1, . . . ,N in the study only reflects the mean treatment effect but ignores that the success or
failure of a specific treatment might depend on additional characteristics of each individual patient. We
describe patient subgroups as a partition fbbg (b = 1, . . . ,B) of all patients i= 1, . . . ,N. The subgroup-
specific model parameters are then ϑ ðbÞ. These parameters can in general be seen as varying coefficients
[8], however they may depend on several patient characteristics and are always step functions with a
different level for each subgroup and not only a smoothly varying coefficient for one single predictive
variable.
Since we are searching for predictive and prognostic factors, we are only interested in subgroups that
differ in the intercept or the treatment effect or both as explained in Section 2.2. With ϑðbÞ= ðαðbÞ, βðbÞ, γ, σÞ`
we assume that the effects of covariates and nuisance parameters are constant for all patients. The partition
fbbg is defined by J partitioning variables Z= ðZ1, . . . , ZJÞ 2z; in other words, fbbg is a hypercube in the
J-dimensional sample space z. These partitioning variables Z are the additional patient characteristics that
potentially influence αðbÞ and βðbÞ. If for example gender were a predictive factor in a given treatment-
endpoint relationship, it would be a patient characteristic that is involved in forming the partitions. If the
partition fbbg is known, the partitioned model parameters ϑðbÞ could be estimated by minimising the
segmented objective function:
ðϑ^ðbÞÞb= 1, ...,B = argminϑ ðbÞ
XN
i= 1
XB
b= 1
zi 2 bbð ÞΨððy,xÞi, ϑðbÞÞ, (3)
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where denotes the indicator function and ðy,xÞi, zi are the realisations of ðY,XÞ and Z for the i-th
patient. This allows us to write the subgroup-specific intercept and treatment parameters as a function of
the partitioning variables
αðzÞ=
XB
b= 1
ðz 2 bbÞ  αðbÞ and βðzÞ=
XB
b= 1
ðz 2 bbÞ  βðbÞ.
Without any a priori knowledge about the partition fbbg, we want to estimate the functions αðzÞ and
βðzÞ by means of model-based recursive partitioning. The main idea underlying this method is the
ability to detect parameter instabilities, i.e. non-constant parameters in a parametric or semiparametric
model, by looking at the score function. Because we are only interested in detecting non-constant
intercepts αðzÞ and treatment effects βðzÞ, we focus on the partial score functions ψαððY,XÞ, ϑÞ=
∂ΨððY,XÞ, ϑÞ=∂α and ψβððY,XÞ, ϑÞ= ∂ΨððY,XÞ, ϑÞ=∂β. If the model parameters are in fact constant
and do not depend on any of the partitioning variables Z, the partial score functions ψαððY,XÞ, ϑÞ
and ψβððY,XÞ, ϑÞ are independent of Z. Consequently, parameter instability corresponds to a correlation
between either of the partial score functions and at least one of the partitioning variables Z1, . . . ,ZJ . In
order to formally detect deviations from independence between the partial score functions and the
partitioning variables, model-based recursive partitioning utilises independence tests. The null
hypotheses
Hα, j0 : ψαððY,XÞ, ϑ^Þ ? Zj, j= 1, . . . , J
and
Hβ, j0 : ψβððY,XÞ, ϑ^Þ ? Zj, j= 1, . . . , J
for a given modelmððY,XÞ, ϑ^Þ state that the partial score functions with respect to α and β, respectively, are
independent of the partitioning variable Zj (j= 1, . . . , J). Hence, these null hypotheses correspond to an
appropriate model fit regarding the intercept and treatment parameter. Because the partial score functions
under the null hypotheses are at least asymptotically normal in many model families, asymptotic M-
fluctuation tests with appropriate correction for multiplicity were introduced for model-based recursive
partitioning by Zeileis and coworkers [9, 7]. Alternatively, permutation tests can be applied in situations
where asymptotic normality of the partial score is not guaranteed [10] or in cases with small numbers of
observations [11–13], which are common in medicine. Also in this case procedures for multiple testing are
used to cope with a possibly large number of partitioning variables J.
If we can reject at least one of the 2 × J null hypotheses for the global model mððY,XÞ, ϑ^Þ at a pre-
specified nominal level, model-based recursive partitioning selects the partitioning variable Zj* asso-
ciated with the highest correlation to any of the partial score functions. This is usually done by means
of the smallest p-value. The dependency structure between the partitioning variable Zj* and either one
of the partial score functions is described by a simple cut-point model. Once we find an optimal cut-
point Zj* < μ using a suitable criterion [13, 7], we split the patients into two subgroups according to
Zj* < μ. For both subgroups, we estimate two separate models with parameters ϑ^ð1Þ and ϑ^ð2Þ, respec-
tively, obtain the corresponding partial score functions, and test the independence hypotheses. If we
find deviations from independence, we in turn estimate a cut-point in the most highly associated
partitioning variable, and split again. The procedure of testing independence of partial score functions
and partitioning variables is repeated recursively until deviations from independence can no longer be
detected.
Since model-based recursive partitioning is a tree method, in the following we use topic-specific
vocabulary, such as nodes. The root node contains all patients and is the basis for the initial model,
inner nodes represent splits and leaf nodes contain the patients of the different subgroups and specify the
partition-specific models. The paths from root to leaf nodes define the subgroups.
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2.2 Content interpretation
A clearer picture of the interpretation of subgroup-dependent model parameters and distribution of the
partial scores under unstable parameters is best given by means of a partitioned linear model discussed in
the following.
Here xA is a contrast that indicates whether a subject was treated with treatment A (active) but not C
(control) in a two-armed trial and xstratum is a stratum with x= ðxA, xstratumÞ. The conditional distribution of
the primary endpoints Y given treatment and stratum is normal
Y jX=x ~nðα+ βxA + γxstratum, σ2Þ. (4)
The segmented model we want to fit using model-based recursive partitioning reads
Y jX= x,Z= z ~nðαðzÞ + βðzÞxA + γxstratum, σ2Þ, (5)
where γ is the effect of the stratum and the variance σ2 is a nuisance parameter. The objective function for a
patient with observations ðy, xÞ is the negative log-likelihood, when maximum likelihood estimation is used,
or the error sum of squares, when ordinary least squares is used. Yet, both methods lead to the same scores
ψððy,xÞ, ϑ^Þ=
∂Ψððy,xÞ,ϑ
∂α

ϑ= ϑ^
∂Ψððy,xÞ,ϑÞ
∂β

ϑ= ϑ^
0
B@
1
CA
`
=
1
σ2
y − ðα^+ β^xA + γ^xstratumÞ
ðy − ðα^+ β^xA + γ^xstratumÞÞ  xA
 !`
(6)
and thus to the same solution. Note that the partial score function with respect to the intercept is
proportional to the least-square residuals and all further scores are proportional to the product of the
residuals and the respective variable.
A partitioning variable can be predictive, prognostic, or both, and we have to consider the parameters
in the model to understand the nature of a partitioning variable. Figure 1 shows examples for mean primary
endpoints and the corresponding intercept α and treatment effect β. If αðzÞ varies over z, but βðzÞ is
constant, then the components of z are prognostic because the mean primary endpoint varies but not the
treatment effect (see first column of Figure 1). If βðzÞ varies over z and αðzÞ is constant, then the variables in
z are predictive since it means that the mean primary endpoint in one treatment arm stays the same but the
treatment effect changes over z (second column). If both parameters vary, then z is predictive (third
column) or predictive and prognostic at the same time (last column). In the latter situation, the mean
primary endpoint of the second subgroup changes over z and the intercept also changes.
It is also interesting to take a closer look at the partial scores. Figure 2a shows the partial scores with
respect to intercept and treatment parameter that result from a linear model Y jX=x ~nðα+ βxA, σ2Þ
plotted against a partitioning variable z1, which is predictive and prognostic. The data-generating process
of this model was suggested by Loh et al. [14] and is defined as
Figure 1: Possible mean primary endpoint within subgroups resulting from a predictive, prognostic, or predictive and prognostic
variable.
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Y jX=x, Z= z ~nð1.9 + 0.2  xA + 1.8  ðz1 < 0Þ+ 3.6  ðz1 > 0Þ  xA, 0.7Þ, (7)
with XA from bð1, 0.5Þ and Z1 fromnð0; 1Þ. For the example, we used this process to draw a sample of 200
observations.
The partial scores with respect to the intercept ψα fluctuate randomly around zero over the whole range
of z1. The partial scores with respect to the treatment parameter ψβ change. Hence, in this situation, model-
based recursive partitioning would detect a deviation from independence between ψβ and z1 and implement
a split at approximately z1 < 0. There is no chance of finding this cut-point by looking at the least-square
residuals only, since a deviation of independence between ψα and z1 is hardly visible in the scatterplot in
Figure 2: Partial scores of different kinds of variables. The symbols represent the treatment arms C and A as indicated. (a)
Partial scores of a predictive and prognostic variable (eq. (7)). (b) Partial scores of a predictive and prognostic variable (eq. (8)).
(c) Partial scores of a prognostic variable (eq. (9)).
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the left panel of Figure 2a. Figure 2b shows the partial scores obtained with a slightly modified data-
generating process, where instead of ðz1 > 0Þ  xA, one has ðz1 < 0Þ  xA:
Y jX= x,Z= z ~nð1.9 + 0.2  xA + 1.8  ðz1 < 0Þ + 3.6  ðz1 < 0Þ  xA, 0.7Þ. (8)
Here the procedure would split the partial score with respect to the intercept, although z1 is still prognostic
and predictive at the same time.
If we focus on the prognostic variable z1 in the model
Y jX= x,Z= z ~nð2  xA + ðz1 > 0Þ, 0.7Þ, (9)
we see non-random patterns in both scores (see Figure 2c). Since the partial scores with respect to the
treatment parameter are set to zero for treatment arm A, we would split on basis of the scores with respect
to the intercept, just as a consequence of a higher power.
These three examples show that splitting in the partial score with respect to the intercept does not give
any information about whether the partitioning variable is predictive or prognostic. It also does not make
sense to choose to split only in the score with respect to the treatment parameter because one might miss
important cut-points. In order to be able to say whether a partitioning variable is predictive or prognostic, it
is not enough to know which partial scores are responsible for the split. It is necessary to consider the
model parameters in the segmented model. If the treatment parameter β varies in the subgroups, then the
chosen partitioning variables are predictive or both predictive and prognostic. If β is constant, the variables
are only prognostic.
2.3 Relation to established procedures
Traditional approaches for subgroup identification are also based on a model for the primary endpoint, but
the segmentation is implemented by means of varying coefficients. More precisely, the model includes
interactions between treatment and the patient characteristics z in addition to the main effects
EðY jX=x, Z= zÞ = α+ βxA + γTprognosticz+ γTpredictivezxA
= ðα0 + γT0, zzÞð1− xAÞ+ ðα1 + γT1, zzÞxA,
(10)
with α= α0, β= α1 − α0, γTprognostic = γ
T
0, z and γ
T
predictive = γ
T
1, z − γ
T
0, z . The model is known as the “classical approach”
for subgroup analyses [15, 16]. Significant interaction terms γpredictive are in this case subject to the choice of
relevant partitioning variables. However, patient subgroups can only be identified directly in this model for
categorical variables zj since the model has no notion of optimal cut-off points. As the number of potential
partitioning variables J might be large, the simultaneous estimation of all parameters in the model might be
computationally burdensome and associated with a large variance. Regularisation procedures may be applied
for selecting relevant interaction parameters that deviate considerably from zero.
RECPAM [17, 18] goes a step further and fits such models by trees. In every node, a likelihood-ratio test
is computed that compares the segmented model
EðY jX= x,Z= zÞ= α+ β1xA ðzj 2 bkÞ+ β2xA½1− ðzj 2 bkÞ (11)
to the constant model
ðEY jX= xÞ= α+ βxA (12)
for every possible segment bk (k = 1, . . . ,K) induced by all possible cut-off points in zj, i.e. an exhaustive
search is performed. The procedure is applied to all partitioning variables zj (j= 1, . . . , J). The algorithm
then chooses the variable and segmentation that comes along with the highest test statistic. The method is
so far limited to linear models and Cox proportional hazards models, and parameter instabilities can only
be detected in β but not in α.
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A method that is similar in spirit to model-based recursive partitioning, but is limited to normal linear
models, is the Gs method [14] based on the GUIDE algorithm [19, 20]. Instead of using partial scores with
respect to intercept and treatment effect, Gs uses only the least-square residuals (that is, only the partial
score with respect to the intercept). In contrast to model-based recursive partitioning, Gs looks at the
dichotomised (at zero) residuals separately in the two treatment arms. The independency between positive/
negative residual signs and each partitioning variable is tested using a chi-squared test separately for each
treatment. If the partitioning variable is at least ordinal, it is dichotomised by splitting at the mean. The
optimal split variable chosen is the one that induces the highest sum of chi-squared statistics. Looking at
the left panels of Figures 2a and 2b, one can imagine that in these situations the procedure may successfully
find the subgroups. However, in a less clear situation and where the optimal cut-point is not near the mean
of z1, the method will have lower power or will not be able to find a split at all.
Another recently proposed tree algorithm is qualitative interaction trees (QUINT [21]). QUINT searches
for instabilities in the treatment parameter β only, but the resulting partitions have to have different signs in
the parameter. In other words, QUINT aims at finding subgroups in which the treatment effect is the reverse
of that of the other subgroups. The current implementation of QUINT [22] is limited to continuous primary
endpoints. It would be possible to enforce splits that are qualitatively different in model-based recursive
partitioning. This could be achieved by incorporating a criterion that implements a split only if the
treatment effects in the two new subgroups have different signs.
SIDES (subgroup identification based on differential effect search) [23] and SIDEScreen [24] aim at
identifying subgroups of patients with high benefit from a novum compared to the standard treatment.
Although the subgroups are linked to hypercubes in the sample space of Z, they are overlapping and can
therefore not be represented as a tree structure. The methods are based on a cross-validated implementa-
tion of subgroups that were obtained on independent learning samples.
More general approaches blending recursive partitioning with traditional models (known as hybrid,
model, or functional trees in machine learning Gama [25]), include M5 [26], GUIDE [19], CRUISE [27], LOTUS
[28] and maximum likelihood trees [29]. (Bayesian approaches can be found in Chipman, George, and
McCulloch [30]) and (Bernardo, Bayarri, Berger, Dawid, Heckerman, Smith, and West [31]). Except GUIDE,
none of these methods has been studied in the specific context of subgroup analyses so far.
3 Partitioning effects of Riluzole on ALS patients
ALS is a neurodegenerative disease that causes weakness, muscle waste and paralysis. Currently the only
drug on the market for treating ALS is Riluzole (Rilutek). It slows down disease progression but only
modestly prolongs life expectancy by about two months [32]. A more thorough investigation of the
treatment effect of Riluzole in ALS patients is of great importance since a cure is not yet available and
patients usually die within 1.5–4 years after disease onset [33]. We use model-based recursive partitioning
to address the question whether Riluzole has an especially low or high treatment effect on both functional
and survival endpoints of any subgroups of patients.
Our analysis is based on patient information obtained from the PRO-ACT (Pooled Resource Open-
Access ALS Clinical Trials) database [34], which contains data of ALS patients that were involved in one
of several publicly- and privately-conducted clinical trials. The database provides information on patient
survival, functional endpoint (the ALS functional rating scale), Riluzole use, demographics, family
history, patient history, forced and slow vital capacity, laboratory data and vital signs. The data were
fully de-identified and therefore the centres of data ascertainment are not given in the data set. The
participants gave their informed consent, and study protocols were approved in the respective medical
centres. The database was initiated by the non-profit organisation Prize4Life that aims at accelerating
cure and drug development for ALS, for example through the DREAM-Phil Bowen ALS Prediction
Prize4Life challenge [35].
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The ALS Functional Rating Scale (ALSFRS [36]), is a widely used instrument for evaluating the
functional status of patients with ALS even though the uni-dimensionality of the score seems questionable
[37]. It is a sum-score of the following ten items: speech, salivation, swallowing, handwriting, cutting food
and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing
stairs, and breathing. Each of these items can have values from zero to four, where four is normal and zero
indicates the inability of performing the respective action. Hence, if the ALSFRS has a value 40, the patient
has normal abilities for all items. The lower the score, the worse is the patient’s status. The items were
measured at several time points during the study period. We focused on the ALSFRS reading approximately
six months after treatment start as the functional endpoint. Approximately means that we used the
measurement closest to six months after treatment start, with a maximal absolute deviation of 20 days.
In addition, we also decomposed the score and modelled the items defining the score separately.
The survival time of patients was measured in days starting with the patient’s enrolment in one of the
trials. For patients without survival information, we used the latest follow-up time given for the patient in
the data as censoring time.
Model-based recursive partitioning was applied to models for the functional and survival endpoints. We
allowed parameter instabilities in both the intercept and the Riluzole treatment effect. Bonferroni-adjusted
permutation tests using test statistics of a quadratic form [13] were applied for assessing independence of
the partial score functions and the partitioning variables and also for cut-point selection. The use of
permutation tests for cut-point selection improves speed compared to the original suggestion of fitting
and comparing models for all reasonable partitions [7]. We restricted the depth of the trees to two levels.
Parameter estimates including confidence intervals are given for the final subgroups. Note that we are
computing the confidence intervals after applying model selection through splitting into subgroups and
thus the intervals should be interpreted with caution. For both endpoints, we used partitioning variables
available at patient enrolment from the following groups of variables: demographics, family history, patient
history, forced and slow vital capacity, laboratory data, and vital signs. We excluded patient records with
missing values at the endpoints; the sample size was N = 2534 for the functional endpoint and N = 3306 with
916 events for the survival endpoint.
3.1 ALSFRS
The ALSFRS six months after treatment start (ALSFRS6) defined the functional endpoint. The sum-score is
positive, and the model needs to adjust for the baseline ALSFRS obtained at treatment start (ALSFRS0). We
used a normal GLM with log-link and offset logðALSFRS0Þ such that the model
E
ALSFRS6
ALSFRS0
jX = x
 
=
EðALSFRS6jX = xÞ
ALSFRS0
= expfα+ βxRg (13)
describes the expected relative change in the ALSFRS over the first six months under treatment. The
treatment (Riluzole/no Riluzole) is indicated by xR. The model was fitted by maximum likelihood.
The time between disease onset and start of treatment, the forced vital capacity (FVC), and the
phosphorus balance are the three partitioning variables selected for the tree given in Figure 3. The FVC
value gives the volume of air in liters that can forcibly be blown out after full inspiration to the lung. A
normal phosphorus balance is between 1 and 1.5 mmol/L. The tree indicates a negative treatment effect of
Riluzole for patients with fewer days between disease onset and start of treatment that have a higher FVC
value (node 4). Therefore, the FVC value is predictive in the group of patients with less than 468 days
between disease onset and treatment start. Patients with more days between disease onset and treatment
start do not seem to have a treatment effect. The fact that the time since onset plays an important role is not
surprising since it is a surrogate for the speed of disease progression [38]. Patients with a slow progression
were seldom included early in one of the studies. Hence a long time between onset and start of treatment
usually stands for a slow progression.
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3.2 ALSFRS items
The model for the ALSFRS sum-score assumes that the effect of Riluzole is the same for the ten items that
define the score. In a more fine-grained analysis, we decomposed the score into its ten items (each ranging
between zero and four) and modelled each item by means of a proportional odds model. For one of the ten
items assessed at six months, e.g. Y6, the model reads
PðY6 ≤ rjX=xÞ = 11 + expð− αr + βxRÞ , (14)
where r =0, . . . , 4 is one of the five possible values of Y . The intercept parameters are now α= ðα0, . . . , α3Þ
and the partial score function ψα is now four dimensional.
As in the previous example, we needed to adjust for the baseline value Y0, i.e. the value of the ALSFRS
item read at the beginning of treatment. This adjustment was implemented by computing separate models;
one each for the observations with a start value k, which allows a baseline-specific intercept and treatment
effect :
PðY6 ≤ rjY0 = k,X = xÞ= 11 + expð− αrk + βkxRÞ
for k =0, . . . , 4. (15)
Therefore, we had a total of five different treatment parameters and 20 different intercepts for each of the
ten different items. Model-based recursive partitioning was used to assess the parameter instability of all
250 parameters simultaneously. Note that some of these parameters could not be estimated owing to too
small of sample sizes; these were simply discarded.
The implementation of the non-standard model in the theoretical and computational framework of
model-based recursive partitioning was straightforward. For every node, we computed the five separate
models for the respective baseline values for each of the ten items and extracted the partial scores.
A stratified permutation test using the baseline values as independent blocks was used to assess parameter
instability. The same procedure was applied for cut-off selection.
The resulting tree (on top of Table 1) contains splits in time between disease onset and treatment start
and in the FVC value. The tree is in good agreement with the tree based on the ALSFRS (Figure 3). The third
split variable is the lymphocyte percentage. Normal lymphocyte concentrations range from 16 to 33%.
Table 1 shows the coefficient values of the models in the terminal nodes for every item and every starting
value of the given item. Empty fields indicate that it was not possible to compute the model. Obviously,
there were not enough observations in models with zero as starting value for any items in any nodes. The
colours in the table indicate whether the effect of Riluzole was positive (blue), negative (pink) or zero (grey).
The colours were assigned on the basis of confidence intervals of the coefficient in the given model.
Riluzole had a positive effect on patients in the partition of terminal node 3 who had a starting value of
4 in item 1 (speech), 3 (swallowing) or 9 (climbing stairs) and on patients in the partition of terminal node 7
that had a starting value of 3 in item 5 (cutting food and handling utensils). Patients in node 4 who had a
starting value of 3 in item 6 (dressing and hygiene) had a negative effect of Riluzole. Riluzole had no effect
on patients in the partition of node 6 which are the patients with more than 584 days between disease onset
and treatment start who have a lymphocyte concentration under 21.5%.
3.3 Survival time
We used both a Weibull model and a Cox model to identify subgroups with differing effects of Riluzole on
the survival endpoint. The application of the model-based recursive partitioning framework in the Weibull
model is straightforward and was introduced by Zeileis et al. [7]. Since the Cox model is a semiparametric
model, where the intercept is a function of time, treated as a nuisance parameter omitted in the partial
likelihood, there is no direct way of obtaining ψα. Because, conceptually, deviance residuals are always
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Table 1: Coefficient and confidence interval of Riluzole use in the terminal nodes for every item and every starting value in the
model-based recursive partitioning with a proportional odds model (ALSFRS items as outcome). Blue indicates a positive effect
of Riluzole, pink a negative effect and grey no effect.
Item No. Start Node  Node  Node  Node 
Speech  

 –. (–., .)
 . (–., .) . (–., .) −. (–., .) −. (–., .)
 . (., .) . (–., .)
Salivation  

 . (–., .) . (–., .) . (–., .) −. (–., .)
 . (–., .) −. (–., .) −. (–., .) −. (–., .)
 . (–., .) −. (–., .)
Swallowing  

 . (–., .) −. (–., .) . (–., .) −. (–., .)
 . (–., .) −. (–., .) −. (–., .) . (–., .)
 . (., .) . (–., .) . (–., .)
Handwriting   −. (–., .)
 −. (–., .) −. (–., .) −. (–., .)
 −. (–., .) . (–., .)
 −. (–., .) . (–., .) −. (–., .) −. (–., .)
 −. (–., .) . (–., .) −. (–., .)
Cutting  
 −. (–., .) −. (–., .)
 . (–., .) . (–., .)
 −. (–., .) −. (–., .) . (–., .) . (., .)
 . (–., .) −. (–., .) −. (–., .) −. (–., .)
Hygiene  

 −. (–., .) −. (–., .)
 −. (–., .) −. (–., –.) . (–., .) . (–., .)
 . (–., .) . (–., .) . (–., .) . (–., .)
Bed  

 −. (–., .) . (–., .)
 . (–., .) −. (–., .) −. (–., .) −. (–., .)
 −. (–., .) −. (–., .) −. (–., .) −. (–., .)
(continued )
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defined as the derivative of the log-likelihood with respect to the intercept, we applied martingale residuals
as ψα. Also worth noting is that both models assume proportional hazards. For the segmented model,
proportional hazards are only assumed within each partition. This has to be kept in mind when interpreting
the treatment effect in different nodes: Parameters with different signs are clearly linked to opposing
treatment effects, but when the parameters only differ in size, it is hard to say whether it is because the
groups differ in treatment effect or because they differ in the hazard function.
3.3.1 Weibull model
The Weibull model is a transformation model of the form
PðY ≤ yjX = xÞ= F logðyÞ− α1 − βxR
α2
 
, (16)
where F is the cumulative distribution function of the Gompertz distribution. Weibull models are fitted via
maximum-likelihood estimation, and therefore the objective function in this case is the negative log-
likelihood and the score function has one column per parameter, i.e. intercept α1, slope parameter β and
scale parameter α2. In the Weibull model, we take the usual intercept as well as the scale parameter as
“intercept”-parameter α= ðα1, α2ÞT because they define the shape of the baseline hazard and hence in some
respect take the role of an intercept. Splitting in the intercept or scale parameter score suggests non-
proportional hazards.
Figure 4 shows that the patient’s age and again the time between onset and treatment start play a role
in the partitioning. Older patients ( > 55.7 years) for whom the time between onset and treatment was longer
than 757 days and very young patients did not seem to benefit at all from the treatment. In the remaining
two groups, life expectancy seemed to be prolonged for patients treated with Riluzole.
3.3.2 Cox model
The use of the Cox model in model-based recursive partitioning is a rather special case, since the baseline
hazard in the Cox model is treated as an infinite-dimensional nuisance parameter and estimation is performed
by minimisation of the negative partial log-likelihood. The Cox proportional hazards model is given by
Table 1: (continued )
Item No. Start Node  Node  Node  Node 
Walking  

 . (–., .) −. (–., .)
 . (–., .) . (–., .)
 . (–., .) . (–., .)
Stairs  
 −. (–., .) −. (–., .) −. (–., .)
 −. (–., .) . (–., .)
 . (–., .) −. (–., .) −. (–., .)
 . (., .) . (–., .) . (–., .) . (–., .)
Respiratory  



 . (–., .) −. (–., .)
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λðyjxÞ= λ0ðyÞ expðβxRÞ, (17)
where λ is the hazard function and λ0 the baseline hazard function. The partial score function ψα (or better,
ψλ0 ) cannot be easily derived. As surrogate score function, we propose using the martingale residuals as a
score for the baseline hazard, which takes the role of an intercept in the Cox model, and the score residuals
for the treatment parameters β. The score residuals are an intuitive choice because they are the first
derivative of the partial log-likelihood with respect to the parameters. We used martingale residuals to
check whether there is a general difference in the endpoint for different patients, which in parametric
models is usually shown by the score with respect to the intercept. Instability in the martingale residuals
indicates a violation of the proportional hazards assumption. Since the martingale residuals are not
normally distributed, the application of permutation tests is more appropriate than the use of M-fluctuation
tests.
Age and the time between disease onset and start of Riluzole treatment form the segments in this
example. The tree in this example has almost the same splits as the tree in the previous example. Also
estimates support the results of the Weibull example. Again, we did not see much difference between
treated and untreated very young patients. For all other groups, Riluzole treatment led to a slight tendency
for a lower risk of death (Figure 5).
4 Discussion
Model-based recursive partitioning allows the direct segmentation of the model describing the overall
treatment effect as specified in the study protocol. This is the most important benefit of embedding
subgroup analysis into this framework because it would be hard to explain why the overall treatment
effect and the partitioned treatment effect have to be estimated by two different procedures. This renders
the application of suboptimal models unnecessary, such as when a change score is analysed using linear
models [21].
Although we are conceptually only interested in finding predictive factors, we think it is necessary to
allow splits in the partial scores with respect to both intercept and treatment parameter. This procedure will
also detect prognostic factors, but there is a higher chance of including all relevant predictive factors since
one might miss prognostic factors when only the treatment scores are split. In our analysis, we decided on
the nature of the partitioning variables (prognostic or predictive) only when we interpreted the results of the
analysis.
In a model with more covariates than the treatment (e.g. strata), we would still split the partial scores
with respect to intercept and treatment parameter for subgroup analyses. A theoretical assumption is then
that the parameters that are not split stay constant. In practice, this assumption usually does not hold. It is
generally also possible to split more than just the scores with respect to intercept and treatment parameter.
Then the split variables are not restricted to being predictive or prognostic but may have an association
with the effect of the other covariates.
In model-based recursive partitioning, the variable selection in each node is error controlled, i.e. the
probability of selecting a partitioning variable for splitting, when actually all partitioning variables are
independent of the scores, is at most as large as the nominal level. The only drawback of using multiple
testing procedures is in cases where there are many possible partitioning variables that do not contain
information, because with increasing number of noise variables the chance of detecting an actually existing
subgroup goes down. The application of permutation tests has the advantage of taking the correlation
structure among the partitioning variables into account. Furthermore, for small studies or small subgroups,
the exact conditional p-value can be easily approximated up to any desired accuracy; therefore, the method
does not rely on asymptotic arguments. The trees obtained by model-based recursive partitioning allow
straightforward visualisation, potentially enriched with plots illustrating the distribution of the endpoints
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for the different treatment groups in each subgroup. Therefore, the results of such a subgroup analysis are
easily communicated to physicians. Looking at a tree is much easier than trying to understand the meaning
of higher-order interactions in a linear predictor. A general drawback of tree methods is the instability of the
tree structure with respect to small perturbations in the data, whereas the resulting partitions we are
primarily interested in are often relatively stable [13]. Instability in the tree structure can be assessed by
means of the variable selection and split statistics, where it is easy to identify all equally likely splits.
Bootstrap aggregation and forest procedures are well-known for their ability to stabilise single trees [39] at
the cost of interpretability and point into a promising future research direction also for model-based
recursive partitioning.
The statistical properties of the confidence intervals derived from the segmented model await further
attention. Leeb and Pötscher ([40]) discuss the validity of inference after variable selection and claim that it
is difficult if at all possible. Bai and Perron [41], who discuss the construction of confidence intervals after
splitting up the data based on a break point in a single partitioning variable, argue that it is possible. In our
approach we first search for the most appropriate partitioning variable (variable selection) and then search
for the optimal split point (break point selection). To our knowledge there is no literature on inference after
variable and break point selection and thus it is unclear if or how valid confidence intervals can be
computed. In any case the results of such a subgroup analysis have to be confirmed in follow-up trials,
which lowers the necessity of confidence intervals. To be conservative one can see the confidence intervals
for parameters in the subgroup-specific models as shown in our examples as a range of possible values and
hence as a measure of variability rather than significance [42].
It would be interesting to extend the framework of the PRO-ACT database of ALS studies to models for
non-independent data, such as mixed models for longitudinal observations. This would allow ALS disease
progression to be modelled over time, and also a potentially time-varying treatment effect to be assessed. In
our way of modelling the functional endpoint, we include no information about patients that died within
the first six months after treatment start. Joint modelling of the longitudinal functional endpoint and the
survival endpoint is a means of combining all possible information [43].
Despite the deficits of model-based recursive partitioning for subgroup analysis discussed in this
section, we think that the procedure as introduced and illustrated in this paper rather closely resembles
the requirements for statistical procedures in this field as outlined in the EMA guideline [1]. In particular, it
is the most generally applicable procedure with statistical error control and unbiased variable selection [13,
7]. With the available open-source implementation (see following section for details), the method can be
applied straightforwardly elsewhere.
Computational details
An open-source implementation of all methods discussed in this paper and beyond is available in the
partykit package hothorn_partykit:_2014. PRO-ACT data are available at https://nctu.partners.
org/ProACT/ [44]. The source code for reading and cleaning the database is provided in the TH.data
package [45]. The source code for the analyses is provided in the supplementary material. All computations
were conducted using partykit (version 0.8-2) in the R system for statistical computing [46], version 3.1.2).
Listing 1: Code snippet for Weibull model in model-based recursive partitioning using the function
ctree( ) from the partykit package.
## Function to compute Weibull model and return score matrix
mywb <- function(data, weights, parm) {
mod <- survreg(Surv(survival.time, cens) Riluzole,
data = data, subset = weights > 0,
dist = "weibull")
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ef <- as.matrix(estfun(mod)[,parm])
ret <- matrix(0, nrow = nrow(data), ncol = ncol(ef))
ret[weights > 0,] <- ef
ret
}
## Compute tree
tree <- ctree(fm, data = data, ytrafo = my.wb,
control = ctree_control(maxdepth = 2,
testtype = "Bonferroni"))
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Abstract
A treatment for a complicated disease might be helpful for some but not all patients, which makes predicting the
treatment effect for new patients important yet challenging. Here we develop a method for predicting the treatment
effect based on patient characteristics and use it for predicting the effect of the only drug (Riluzole) approved for treating
amyotrophic lateral sclerosis. Our proposed method of model-based random forests detects similarities in the treatment
effect among patients and on this basis computes personalised models for new patients. The entire procedure focuses on
a base model, which usually contains the treatment indicator as a single covariate and takes the survival time or a health
or treatment success measurement as primary outcome. This base model is used both to grow the model-based trees
within the forest, in which the patient characteristics that interact with the treatment are split variables, and to compute
the personalised models, in which the similarity measurements enter as weights. We applied the personalised models
using data from several clinical trials for amyotrophic lateral sclerosis from the Pooled Resource Open–Access Clinical
Trials database. Our results indicate that some amyotrophic lateral sclerosis patients benefit more from the drug Riluzole
than others. Our method allows gradually shifting from stratified medicine to personalised medicine and can also be used
in assessing the treatment effect for other diseases studied in a clinical trial.
Keywords
Personalised medicine, individual treatment effect, random forest, model-based recursive partitioning
1 Introduction
Amyotrophic lateral sclerosis (ALS) is a deadly disease that aﬀects motor neurons in the brain and spinal cord, i.e.
the neurons responsible for voluntary muscle control. Riluzole (Rilutek) is the only approved drug for this disease
to date. According to the European Medicines Agency,1 Riluzole prolongs the median survival of ALS patients,
depending on the dose, by a few months. Several side eﬀects, such as sickness, weakness or increased liver enzyme
levels are mentioned.1 Knowledge how Riluzole works on the nervous system of ALS patients is limited. The
Pooled Resource Open–Access Clinical Trials (PRO-ACT) database2 is the largest database containing clinical
trial data of ALS patients available and was initiated to retrieve more information on the disease. It contains data
from 17 ALS studies conducted between 1990 and 2010. Using these data, we aimed at ﬁnding out more about the
eﬀect of Riluzole on the health and survival of patients.
Before statistical analyses and p-values entered into medical progress 70 years ago, doctors treated patients
individually based on their experiences and knowledge.3 Since the beginning of the ‘golden age of randomised
clinical trials’, however, medication became more and more standardised. Nowadays, much knowledge about the
eﬀect of drugs has accumulated, cornerstone drugs such as antibiotics have been used for decades and many
diseases can be treated successfully; however, providing new drugs for the general public becomes more diﬃcult.
Diseases such as ALS are too complex to treat all patients in the same way. Therefore, there is a need to return to
more individualised treatments, but this time with the use of statistical concepts.
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In the past years, there has been an immense eﬀort towards personalised medicine in the analysis of randomised
controlled trials. The goal is to identify predictive factors, i.e. factors that interact with the treatment,4 such as
biomarkers, other treatments and environmental circumstances. In the following, we will refer to these factors as
patient characteristics. Prognostic factors, i.e. factors that directly aﬀect the patient’s outcome, are only of
secondary interest, but should not be neglected, because they not only change the general level of the outcome
– showing in the individual intercept – but might also be predictive and prognostic.5 Note that we use the terms
predictive and prognostic as in the medical literature,4 but in a statistical sense both groups of variables are useful
predictors. For drugs for which the biological mode of action is unknown, predictive and prognostic factors
should ﬁrst be identiﬁed in a data-driven way. New hypotheses can then be generated and new trials can be
planned based on these hypotheses. In this ﬁrst step, we ask whether a certain patient characteristic is relevant and
not why.
Many new statistical methods in the ﬁeld of stratiﬁed medicine, i.e. subgroup analysis, have been developed.
Subgroup analyses aim at ﬁnding groups of patients that have diﬀerential treatment eﬀects. Most of the methods
are based on recursive partitioning (trees) and/or interaction models.6–12 The tree-based methods for subgroup
analyses have specialised splitting procedures for partitioning the patients into groups with higher and lower
treatment eﬀect. Interaction models evaluate the interaction between the treatment and given patient
characteristics. The idea behind methods of subgroup analyses in general is to obtain a treatment eﬀect ðzÞ
that depends on the patient characteristics z. For example, the treatment eﬀect could depend on the age of
patients, in which patients less than 40 years of age improve through the treatment, patients between 40 and 60
do not improve and patients older than 60 years improve, but less than the patients under 40 years:
ðzÞ ¼
1 if zage5 40
0 if 40  zage5 60
0:5 if 60  zage
8<: ð1Þ
However, the assumption that the treatment eﬀect is a step function may be too restrictive, and ðzÞ in reality
may be a smooth interaction function. In other words, personalised medicine is required instead of stratiﬁed
medicine. Because methods for subgroup analyses again generalise the treatment eﬀect for a group of patients,
it can only be considered as a step in the direction toward personalised medicine. We provide a method that can
estimate smooth treatment eﬀect functions using model-based random forests and weighted models. More
importantly, this method provides an estimate for the treatment eﬀect of a future patient, thereby allowing a
decision to be made whether treatment of this patient is appropriate.
2 Methods
Seibold et al., 20165 introduced a means of conducting subgroup analysis for randomised controlled trials using
model-based recursive partitioning. One ﬁrst deﬁnes a modelMððY,XÞ,#Þ with primary endpoint Y, covariates X
including the randomised treatment indicator
XA ¼ 1 if patient received the ðnewÞ treatment0 if patient received no treatment ðor standard of careÞ,

ð2Þ
and parameter vector #. In the following, we will consider likelihood models (e.g. generalised linear models or
parametric survival models) where the model parameters # can be estimated by maximising the log-likelihood
‘ ððY,XÞ,#Þ of those models (e.g. Gaussian log-likelihood or Weibull log-likelihood) or equivalently by solving the
score equation XN
i¼1
sðð y, xÞi,#Þ ¼ 0 ð3Þ
with
sðð y, xÞi,#Þ ¼
@‘ ðð y, xÞi,#Þ
@#
ð4Þ
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In most applications, the model contains only an intercept  and a treatment eﬀect , i.e. X ¼ ð1,XAÞ
and # ¼ ð,Þ>, but more parameters are possible, such as coeﬃcients of additional regressors or scale and
shape parameters for the response distribution. Technically, there can also be more than two treatment
groups or no intercept. For simplicity, we will focus on the basic case with intercept and treatment
eﬀect and two treatment groups. The method obtains subgroups fBb¼1,...,Bg that diﬀer with regard to the
treatment eﬀect  and potentially the intercept . The subgroups are deﬁned by patient characteristics
Z ¼ ðZ1, . . . ,ZJÞ 2 Z. Hence, the intercept and treatment parameters can be written as a function of the
subgroup-deﬁning variables z. In other words, the patient characteristics Z are not part of the model
MððY,XÞ,#Þ but are used to deﬁne the subgroups in which the model parameters diﬀer, and then the model
parameters are estimated within each subgroup.
Conceptually, the partitioned model parameters ðzÞ and ðzÞ might depend on z in a more complex way
than a simple tree structure. Therefore, the model parameters are not step functions, but rather smooth
interaction functions, so that an individual treatment eﬀect (as in personalised medicine) can be computed for
each patient instead of only for each subgroup of patients (as in stratiﬁed medicine). The function ðzÞ can then
be understood as an estimate of the counterfactual individual treatment eﬀect of a patient with patient
characteristics z.
The most intuitive step from a tree structure to a more complex structure is to use a random forest instead of a
single tree. Hence, we propose a strategy in which a model-based random forest is used to measure how similar
patients are with respect to the treatment eﬀect and the treatment eﬀect of each patient is predicted on this basis
using personalised models.
2.1 Random forest
Random forests13 compute an ensemble of T trees. The proposed algorithm draws subsamples Lt, t ¼ 1, . . . ,T of
the given N observations and ﬁts a model-based tree to each subsample using a randomly sampled set of candidate
split variables z. The data Lct that were not in the learning sample for tree t are called out-of-bag data. Classical
random forests provide information on the similarity between observations with respect to the response. Model-
based random forests provide information on the similarity between observations (patients) with respect to the
model parameters, i.e. treatment eﬀect and intercept.
This section focuses on the estimation of the trees, and the following section features the computation of the
similarity measure and how the forest can be used to estimate personalised treatment eﬀects.
2.2 Split procedure
The special feature of our method is the split procedure, which is based on the empirical estimating function
s ¼
sðð y, xÞ1,b#Þ sðð y, xÞ1,b#Þ
sðð y, xÞ2,b#Þ sðð y, xÞ2,b#Þ
..
. ..
.
sðð y, xÞN,b#Þ sðð y, xÞN,b#Þ
0BBB@
1CCCA ð5Þ
which contains the score contributions sðð y, xÞi,b#Þ and sðð y, xÞi,b#Þ. The score contributions are
the partial derivatives of the log-likelihood with respect to  or , respectively, evaluated at the N
observed data points and the estimated parameters b# ¼ ð^, ^Þ>.14 The matrix of score contributions s
contains information on the deviation from the model ﬁt for all parameters and observations of a given model
MððY,XÞ,#Þ. The contributions can thus be seen as residuals. Score contributions are widely used in
model inference (e.g. see Chapter 3.7, Tutz, 2012)15 and in recursive partitioning.14,16 They are particularly
useful because they ﬂuctuate randomly around 0 in well-ﬁtting models, and they show patterns when there are
parameter instabilities.
To obtain a split in model-based recursive partitioning for this setup, the following steps have to be performed:
. Estimate the parameters in the prespeciﬁed model MððY,XÞ,#Þ.
. Compute the associated score matrix s.
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. Perform tests of independence between the score contributions and the partitioning variables:
H,j0 : sððY,XÞ,b#Þ ? Zj
H,j0 : sððY,XÞ,b#Þ ? Zj j ¼ 1, . . . , J
The smallest p-value corresponds to the greatest deviation from the model assumption; that intercept and
treatment parameter are the same for all patients in the given node/subgroup.
. If any p-value is lower than the signiﬁcance level, select the partitioning variable that has the highest association
(lowest p-value) to any of the relevant residuals for the split.
. Search for the optimal split point in the selected partitioning variable using a suitable criterion, such that the models in
the resulting daughter nodes have as little association between the partitioning variable and the residuals as possible.
This split procedure is repeated until a stopping criterion is met. This can be, for example, when no p-values are
lower than the signiﬁcance level or if subgroups become too small. For detailed information on stopping criteria,
see Hothorn et al., 2015.17 In the end, a tree is obtained with disjoint subgroups[
b
Bb ¼ Z ð6Þ
Accordingly in a random forest of T trees, each tree deﬁnes disjoint subgroups[
b
Btb ¼ Z 8t ¼ 1, . . . ,T ð7Þ
The independence tests can be performed using permutation tests18,19 or, for reasonably large samples, using
M-ﬂuctuation tests.14,20 Unbiased recursive partitioning methods commonly use tests with node-wise null
hypotheses of ‘no further split needed’, as we do here.14,16,19 Since one test is computed per patient
characteristic eligible in the given node, multiplicity adjustment such as Bonferroni correction is recommended.
More details on the algorithm and the test procedures used are documented in Appendix 2.
2.3 Personalised models
In personalised medicine, the goal is to learn how much a person will proﬁt from a given treatment and what
would happen if the standard of care or no treatment is given. For any patient, it is possible to compute a
personalised model based on the similarity of this observation to the observations in the training data. In
general, any measure of similarity wiðzkÞ between patients i and k with respect to the treatment eﬀect and
general health could be used, i.e. any measure that compares patients i and k in terms of ðziÞ to ðzkÞ and of
ðziÞ to ðzkÞ. A straight forward similarity measure in this sense is the number of times patients i and k are
classiﬁed in the same subgroup by the single model-based trees in the random forest
wiðzkÞ ¼
XT
t¼1
XBt
b¼1
ðzi 2 BtbÞ ^ ðzk 2 BtbÞ ð8Þ
with T being the number of trees used for the computation of the forest and Bt being the number of subgroups
from tree t.21–23 If patient i is part of the training set, the weights can be computed out-of-bag, i.e. the only trees
(t ¼ 1, . . . ,T) considered are those where patient i is not in the subset Lt for the computation.
To obtain the personalised modelMððY,XÞ,b#ðziÞÞ for patient i, the base model is recomputed with the weighted
training data, which is equivalent to minimising the personal log-likelihood of patient i (the sum of weighted log-
likelihood contributions)
argmax
#
XN
k¼1
wiðzkÞ  ‘ ðð y, xÞk,#ðziÞÞ ð9Þ
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In other words, every patient k from the training set is included wiðzkÞ times in the ‘new data set’ to compute the
personalised model for patient i. In the following, the parameters estimated from this model will be denoted byb#ðziÞ ¼ ð^ðziÞ, ^ðziÞÞ.
Using the personalised models, it is possible to obtain a log-likelihood. From the personalised model for patient
i, the log-likelihood contribution ‘ ðð y, xÞi,b#ðziÞÞ for this observation is computed. The log-likelihood then isXN
i¼1
‘ ð y, xÞi,b#ðziÞ  ð10Þ
which we refer to as forest log-likelihood. A variant of this algorithm for non-personalised transformation models
is discussed in Hothorn and Zeileis.24
2.4 Improvement through personalised models
To check whether the personalised models actually lead to an improvement of the base model, one tests the hypothesis
H0 :
ðZÞ  |ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
H
0
ð11Þ
\
ðZÞ  |ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
H
0
ð12Þ
This strict null hypothesis is to be rejected if any of the patient characteristics contain information on the
outcome or the treatment eﬀect. To conduct the test, one can proceed as follows:
. Compute the forest log-likelihood and the log-likelihood of the base model and calculate their diﬀerence. This
diﬀerence is a measure of how much better the personalised models are compared to the base model.
. Draw parametric bootstrap samples from the base model.
. Compute the forest log-likelihood and the log-likelihood of the base model in the bootstrap samples and again
compute the diﬀerences. The distribution of these values represents the distribution under the null hypothesis.
. The p-value is then the proportion of bootstrap samples in which the diﬀerence in log-likelihoods exceeds the
observed diﬀerence in the original data. Note, that this p-value will be very low or even 0 when the patient
characteristics contain information on the outcome or the treatment eﬀect.
In practice, one may be interested in just H0 , but testing the sub-hypotheses H

0 and H

0 separately is not
straight-forward. An approximation would be to compute the personalised models using a forest that splits based
only on the partial score function with respect to  or . Patient characteristics, however, are often not exclusively
predictive or prognostic but can be both. Also, if a patient characteristic is purely prognostic, this still may result in
a pattern in both partial score functions. For more details, see Seibold et al, 2016.5
2.5 Dependence plots
A partial dependence plot describes the dependence of a function (in our case the treatment eﬀect ^ðzÞ) and a
variable (in our case, a partitioning variable).25 The partial dependence plot resulting from a model-based tree
would show a step function. The partial dependence from a random forest can be smoother for continuous
partitioning variables. It can be obtained by plotting ^ðzj Þ against zj for each partitioning variable j ¼ 1, . . . , J.
2.6 Variable importance
The variable importance for the random forest is computed based on the tree log-likelihoods. For a given forest
computed with T trees, the log-likelihood is computed as follows:
. Select the out-of-bag data Lct and determine the terminal node/subgroup to which each observation i belongs.
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. Compute the log-likelihood contribution of each observation i 2 Lct based on the respective model in the
terminal node/subgroup with parameters b#ðziÞ.
. Compute the out-of-bag log-likelihood as the sum of the contributions
‘t ¼
X
i2Lct
‘ ðð y, xÞi,b#ðziÞÞ ð13Þ
To obtain the variable importance of a given variable zj, j ¼ 1, . . . , J, the variable is permuted. The log-
likelihood is computed as above, except that the column with information about zj in the out-of-bag data is
replaced by the permuted zj. We denote the log-likelihood of tree t with variable zj permuted by ‘
ð j Þ
t . The variable
importance is then
VIj ¼ 1
T
XT
t¼1
‘t  ‘ð j Þt
h i
ð14Þ
If the variable importance is high, the variable is an important predictive and/or prognostic factor. Note that
due to the signed diﬀerences, the variable importances might become negative signalling that the log-likelihood
merely improved by chance and that the variable is not important. As the size of the negative values conveys
information on the overall importance variability, we do not collapse to 0 which would otherwise be a sensible
restriction. It is possible to compute also conditional variable importances26 to account for correlation between
patient characteristics. In the following, we focus on unconditional variable importances.
3 Results
3.1 PRO-ACT data
The PRO-ACT (https://nctu.partners.org/ProACT) database contains longitudinal data of ALS patients that
participated in one of 16 phase II and III trials and one observational study. It is a project initiated by the
non-proﬁt organisation Prize4Life (http://www.prize4life.org/) to enhance knowledge about ALS. It contains
information on a broad variety of patient characteristics, such as vital signs, the patient’s and family’s history,
and treatment information. Identiﬁcation criteria, such as study centres, are not included in the database. Also
collected are the survival time and the ALS functional rating scale (ALSFRS), which is a score measuring the
patients’ ability of living a normal life.27 The ALSFRS is a sum-score of 10 items, each of which ranges between 0
and 4, where 0 represents complete inability and 4 represents normal ability. The items are speech, salivation,
swallowing, hand-writing, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting
bed clothes, walking, climbing stairs and breathing. As outcomes in the study, we used both the survival time
(denoted by survival) and the ALSFRS 6 months after treatment start (denoted by ALSFRS6) and identiﬁed
patient characteristics that inﬂuence the eﬀect of Riluzole on these outcomes. For the two outcome variables, we
obtained two diﬀerent data sets. We only included observations that contain information on the respective
outcome variable and only patient characteristics that have fewer than 50% missing values. The survival time
data set contains 3306 observations and 18 patient characteristics. The ALSFRS data set contains 2534
observations and 57 patient characteristics.
Tables 1 and 2 show the estimates including standard errors obtained from the base model for each outcome.
For the ALSFRS, this base model is given by
E
ALSFRS6
ALSFRS0
X ¼ x  ¼ EðALSFRS6jX ¼ xÞALSFRS0 ¼ expfþ xAg ð15Þ
Table 1. ALSFRS base model (Gaussian generalised linear model with log-link and offset).
Estimate Std. error 2.5% 97.5%
 0.1595 0.0065 0.1722 0.1468
 0.0091 0.0077 0.0060 0.0242
Given are the parameter estimates, their standard error and the Wald confidence interval.
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which represents a Gaussian generalised linear model with log-link and oﬀset logðALSFRS0Þ, where ALSFRS0 is
the ALSFRS that was measured at the time of treatment start. The base model for the survival time is given by the
Weibull model
PðT  survivaljX ¼ xÞ ¼ F logðsurvivalÞ  1  xA
2
 
ð16Þ
where F is the cumulative distribution function of the Gompertz distribution. Note that the Weibull model has a
scale parameter in addition to the intercept, so that both 1 and 2 control the appearance of the baseline hazard.
In the notation of equation (4), this leads to # ¼ ð1,2,Þ>.
3.2 Personalised models
We computed personalised models for all observations in the respective training data, which were used to obtain
the random forest. The distribution of parameter estimates in the personalised models is given in Figure 1 for the
ALSFRS and in Figure 2 for the survival time. Figure 1 shows that all patients are predicted to have a positive
Riluzole eﬀect, i.e. for all patients taking Riluzole, a higher ALSFRS is achieved compared to those not taking
Riluzole. However, there is a variability in the treatment eﬀects, and the distribution of the treatment eﬀect is
bimodal (as is the distribution of the intercept). The treatment eﬀect estimated from the base model is between the
two modes. The lowest treatment eﬀect a person in this data set is predicted to have is 0.0027.
For the survival time, the lowest predicted treatment eﬀect is 0.0717. However, the value of the treatment eﬀect
in the personalised survival models cannot be interpreted in isolation; its meaning depends on the shape of the
Figure 1. Kernel density estimates of the personalised parameter estimates for the ALSFRS.
Table 2. Survival time base model (Weibull model).
Estimate Std. error 2.5% 97.5%
1 6.7070 0.0323 6.6437 6.7703
 0.1073 0.0387 0.0314 0.1832
logð2Þ 0.5833 0.0271 0.6364 0.5302
Given are the parameter estimates, their standard error and the Wald confidence interval.
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baseline hazard, i.e. on 1 and 2. Instead of depicting the densities of the two baseline hazard parameters, in
Figure 2, we show the baseline hazard curves. The baseline hazard varies for diﬀerent patients, and there is a gap in
the middle. The baseline hazard estimated from the base model lies close to that gap.
From the personalised models, we obtained the ‘forest log-likelihoods’ for both outcomes. For the Gaussian
GLM with log-link and oﬀset, the log-likelihood contribution for observation i is deﬁned as
l ðALSFRS6,ALSFRS0, xÞi,b#ðziÞ 
¼ ALSFRS6i  exp x>i b#ðziÞ  ALSFRS0i 2 ð17Þ
with xi ¼ ð1,xAiÞ> and b#ðziÞ ¼ ð^ðziÞ, ^ðziÞÞ>. For the Weibull model, the log-likelihood contribution for
observation i is
l ðsurvival, xÞi,b#ðziÞ  ¼ i logð^2ðziÞÞ  i survivali  x>i b#ðziÞ^2ðziÞ þ exp survivali  x
>
i
b#ðziÞ
^2ðziÞ
 !
ð18Þ
with xi ¼ ð1,xiAÞ>, b#ðziÞ ¼ ð^1ðziÞ, ^ðziÞÞ> and i as the censoring indicator.
As can be seen in Figures 3 and 4, the forest log-likelihoods are higher than the log-likelihoods of the base
models for both the ALSFRS and the survival time. The ﬁgures show the diﬀerence in log-likelihood between the
forest and the corresponding base model. To show that this diﬀerence is not due to overﬁtting, we drew 50 samples
from the base models, i.e. 50 parametric bootstrap samples for which the assumption holds that the intercept (or
baseline hazard) and treatment eﬀect are the same for all patients. ALSFRS values are drawn from a normal
distribution truncated at 0 to assure positivity. (The eﬀect of truncation is virtually negligible; only two
observations had a truncation probability of more than 1%.) The survival times are drawn from a Weibull
distribution censored at the originally observed censoring times (if exceeded). The diﬀerences in log-likelihoods
for both ALSFRS and survival time are distributed close to 0, with a slight shift to the right, for the parametric
bootstrap samples. The large diﬀerence in the ALS data supports the assumption that the base models are not ideal
and personalised models are meaningful (the respective p-values are both 0). To approximately check the sub-
hypotheses given in equations (11) and (12), we also computed log-likelihoods of the two forests that split only
with respect to one of the partial score functions – either intercept (or baseline hazard) or treatment eﬀect. For the
ALSFRS, both the forest under H1 (computed with splitting only based on the partial score function with respect
to the intercept ) and the forest under H1 (computed with splitting only based on partial score function with
Figure 2. Distribution of the personalised parameter estimates for the survival time. The baseline hazard functions are given in the
left panel; the kernel density estimate of the treatment effect estimate is given in the right panel.
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respect to the treatment eﬀect ) lead to greatly improved models compared to the base model. The diﬀerence in
log-likelihood between the forest underH1 and the base model is even greater than between the original forest (H1)
and the base model. For the survival time, the log-likelihoods of the original forest and the forest under H1 (based
on splits in the partial score function with respect to the baseline hazard) are very close to each other. Splitting
based only on the partial score function with respect to the treatment eﬀect (H1) already improves the log-
likelihood but not as much as splitting based on both intercept and treatment eﬀect (H1). The good
performances of the forests under H1 indicate that (a) there are no predictive patient characteristics, (b) all
predictive patient characteristics are also prognostic or (c) the predictive nature of the predictive patient
characteristics are so strong that it has enough impact on the structure of the partial score function with
respect to .
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Figure 4. Difference in log-likelihoods between forest and base model using the original data (dashed lines; H1, the usual forest; H

1 ,
the forest that splits based on ; H1 , the forest that splits based on ) and using 50 samples simulated from the base model (density
curve) for the survival outcome.
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Figure 3. Difference in log-likelihoods between forest and base model using the original data (dashed lines; H1, the usual forest; H

1 ,
the forest that splits based on ; H1 , the forest that splits based on ) and using 50 samples simulated from the base model (density
curve) for the ALSFRS outcome.
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3.3 Dependence plots
The dependence plots as shown in Figures 5 and 6 can be obtained for any partitioning variable. Here we show the
dependence plots for the four variables with the highest variable importance (see Section 3.4). For continuous
variables, such as age, we show a scatter plot, as before. For categorical variables, such as the variable weakness,
which indicates whether a patient suﬀers from muscle weakness (yes/no), boxplots giving the variation of ðzÞ and
a square representing ðzÞ, i.e. the mean, are a meaningful way of representing the dependence between treatment
eﬀect and the given variable.
The most obvious pattern of the four graphs in Figure 5 is shown in Figure 5(d), in which the personalised
treatment eﬀects are plotted against the forced vital capacity (FVC). Patients with a low lung function (low FVC)
are predicted to have a higher treatment eﬀect than those with better lung function. The graph shows a relatively
clear cut at approximately 3 L. This indicates that FVC is a predictive factor. For the time between disease onset
and treatment start, the pattern is less clear. Patients with a short as well as those with a long time between disease
onset and treatment start seem to beneﬁt most. Also for the creatinine value, which indicates kidney function, only
weak patterns are observed. The phosphorus balance is slightly negatively associated with the treatment eﬀect.
Figure 5. Dependence plots for the four patient characteristics with the highest variable importance from the ALSFRS forest. (a)
Dependence plot for the time in days between disease onset and treatment start. (b) Dependence plot for the creatinine level in
mmol/L. (c) Dependence plot for the phosphorus level in mmol/L. (d) Dependence plot for the forced vital capacity (volume of air in
litres that can forcibly be blown out after full inspiration).
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For the survival time, plotting only the treatment eﬀect against a variable is not meaningful since the
interpretation of the treatment eﬀect depends on the shape of the baseline hazard. Therefore, we took a
diﬀerent approach in this case and show on the y-axis the diﬀerence in median survival between treatment and
control intake. For example, a value of 70 means that based on the personalised model of this patient, the median
survival is prolonged by 70 days if the patient takes Riluzole. The diﬀerence in median survival is denoted by 0:5.
Any other quantile could be used as well since from the Weibull model, information on the entire estimated
distribution in the two treatment groups is obtained. Taking the diﬀerence in medians makes sense because it is a
measure on the scale of the outcome, just as the treatment eﬀect in a linear model, which is the diﬀerence in means.
The shape of 0:5 when plotted against age shows a strong pattern that indicates that age is a predictive factor (see
Figure 6). The treatment eﬃcacy increases with age until about 55 years and then ﬂattens. The diﬀerence in median
survival slightly increases with the days between disease onset and start of treatment in the beginning, but
decreases again after about 1000 days. Patients who suﬀer from weakness have a greater variance in their
beneﬁt from Riluzole. Tall patients are predicted to beneﬁt little on average.
3.4 Variable importance
Figures 7 and 8 show the variable importance of each split variable. Figure 7 suggests that the time between disease
onset and start of treatment plays the most important role for the personalised models. The time between disease
Figure 6. Dependence plots for the four patient characteristics with the highest variable importance from the survival time forest. (a)
Dependence plot for the age. (b) Dependence plot for the time in days between disease onset and treatment start. Outlier has been
omitted in the estimation of the smooth curve. (c) Dependence plot for the weakness indicator. (d) Dependence plot for the height.
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onset and start of treatment, the FVC, and the phosphorus balance have been shown to be the most important
variables for stratiﬁed models,5 which is underlined by this analysis. The time between disease onset and start of
treatment contains information on the state of disease progression for patients in the trial. If the disease onset and
the start of treatment are far apart, the patient is likely to have a slow progression.28 Also Riluzole has been shown
to not be eﬀective when the disease is already far progressed.1 Thus, it is not surprising that this variable is selected
as an important variable.
For the Riluzole eﬀect on the survival time, the patient’s age and again the time between onset and treatment
start play a role. Both variables have been identiﬁed before5 as important factors for survival time.
4 Discussion
Model-based forests can ﬁnd important predictive and prognostic patient characteristics and – more importantly –
via the personalised models provide the possibility to predict the counterfactual individual treatment
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Figure 7. Variable importances of all split variables used for the ALSFRS forest.
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eﬀect of a future patient. The personalised models allow a shift from standardised medicine back to
personalised medicine, but this time in a controlled way by using statistical principles. Through analysis
of the PRO-ACT data and simulations (see Appendix 3), we showed that personalised models can perform
better than the standard global model if there are diﬀerences in treatment eﬀect between patients. If there is no
diﬀerence, the performance of the methods is about the same. In our performance checks, we focused on the ﬁt of
the model to the data based on the log-likelihood. Performance of the method for new patients was studied using
simulations.
The proposed method is applicable to clinical trial data where treatment is randomised. In our
analysis of the PRO-ACT data, we included several clinical trials for which we have no knowledge about
inclusion criteria or any other details of the study protocol as this information is not given out in order to
anonymise data. This could possibly lead to confounding issues. As there is interest in methodology for when
treatment is not randomised, we included a small simulation study on this topic in Appendix 4. The results seem
promising in the case where the patient characteristic that impacts the treatment assignment is not the predictive
factor. However, there is a bias when a patient characteristic is predictive and also impacts treatment assignment.
Further work in the area of observational trials is needed where, e.g. adjustment methods such as propensity
scoring29 could be of use.
The presented methods are based on tree-based subgroup analyses but go a step further.
Not only are subgroups identiﬁed and the treatment eﬀect within each group estimated, but many slightly
varying trees are used to retrieve a measure of similarity between patients. On this basis, a model is computed
in which more similar patients are weighted higher. The personalised models provide point estimates for the
treatment eﬀect. When the individual treatment eﬀects are plotted against patient characteristics, researchers
can determine whether the patient characteristics are predictive factors and in what way the patient
characteristics and the treatment interact. For ALS patients, the FVC value was predictive for the ALSFRS,
and the patient’s age and height were predictive for survival. The next step would be to generate hypotheses from
these ﬁndings and plan a study to test these. Our method oﬀers a promising means of providing individual
treatment eﬀect predictions and can be applied to any clinical trial data where baseline patient characteristics
are available.
All results were obtained solely using open-source implementation software (see Section 5), which provides easy
access to the methods.
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Figure 8. Variable importances of all split variables used for the survival time forest.
Seibold et al. 13
Paper II - 57 -
5 Computational details
The code for data preprocessing of the PRO-ACT data is available in the TH.data package.30 The source code for
the full analyses is available on https://github.com/HeidiSeibold/personalised_medicine. Implementation of all
methods discussed in this article is based on the R partykit package (version 1.0-2).31 Other R packages used
were sandwich (2.3-3),32,33 survival (2.38-1),34 eha (2.4-2)35 and ggplot2 (2.0.0).36 All computations were conducted
in the R system for statistical computing (version 3.2.0).37
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Appendix 1
Notation
b ¼ 1, . . . ,B subgroup number
B subgroup
i, k ¼ 1, . . . ,N observation number
j ¼ 1, . . . , J patient characteristics number
‘ log-likelihood
L data sample (Lt training sample tree t, Lct out-of-bag sample tree t)
M model
S score (derivative of the log-likelihood s ¼ @l=@#, partial derivatives are denoted by s, s, etc.)
t ¼ 1, . . . ,T tree number
w weight
X model covariates (including treatment indicator XA)
Y response
Z patient characteristics
 intercept
 treatment effect
# model parameters # ¼ ð,, . . .Þ>
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Appendix 2
Split algorithm in detail
In the following, the split algorithm in model-based recursive partitioning is explained. The split procedure starts
with all N data points. In nodes other than the root node, the size of the data set depends on the previous splits.
For notational simplicity, we describe the split procedure in the root node, i.e. for patients i ¼ 1, . . . ,N.
. Compute prespeciﬁed (parametric) model MððY,XÞ,#Þ. Estimate b# by maximising the log-likelihoodb# ¼ argmax
#
‘ ððY,XÞ,#Þ
or equivalently by solving XN
i¼1
sðð y, xÞi,#Þ ¼ 0
for #.
. Compute associated empirical estimating function (residuals)
s ¼
s^ðð y,xÞ1,b#Þ s^ðð y, xÞ1,b#Þ
s^ðð y,xÞ2,b#Þ s^ðð y, xÞ2,b#Þ
..
. ..
.
s^ðð y, xÞN,b#Þ s^ðð y, xÞN,b#Þ
0BBBB@
1CCCCA
. Perform tests of independence between residuals (partial score vectors) s^ as well as s^ and partitioning
variables Zj.
H,j0 : s^ððY,XÞ,b#Þ ? Zj
H,j0 : s^ððY,XÞ,b#Þ ? Zj j ¼ 1, . . . , J
For the tests, we use permutation testing with the linear statistic
Tj ¼
X
i2Bb
gjðZjiÞ  sðð y, xÞi,b#Þ, sðð y, xÞi,b#Þ 
The transformation function g depends on the scale of the variable Zj. If Zj is numeric, then gj ðzjiÞ ¼ zji. If Zj is
categorical with K categories, then gj ðzjiÞ ¼ eKðzjiÞ ¼ ðIðzji ¼ 1Þ, . . . , Iðzji ¼ KÞÞ>, i.e. gj is the unit vector of length
K, where the element that corresponds to the value of zji is one. Note that Tj is two-dimensional for numeric
patient characteristics and 2 K-dimensional for categorical patient characteristics. If there are missing values in
Zj, the observations are excluded from the sum so that we actually sum over all observations i 2 Bb, except for the
observations in Bb, where Zj is missing. The standardised test statistic is the Pearson correlation coeﬃcient
cðtj,j,j Þ ¼ ðtj  j Þﬃﬃﬃﬃﬃﬃﬃﬃﬃðj Þp


if Zj is numeric and otherwise
cðtj,j,j Þ ¼ max
k¼1,...,K
ðtj  j Þkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃðj Þkkp


The conditional expectation j and covariance j can be derived as in Strasser and Weber.
38 The smallest p-
value corresponds to the largest discrepancy from the model assumption that intercept and treatment parameter
are the same for all patients in the given node/subgroup.
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. If any Bonferroni-adjusted p-value is lower than the signiﬁcance level, select the partitioning variable Zj that
has the highest association (lowest p-value) to any of the residuals relevant for the split.
. Select as split point the point that results in the largest discrepancy between score functions in the two resulting
subgroups. The discrepancy can be measured by the linear statistic
Tkj ¼
X
i2B1k
si
where B1k here is the ﬁrst of the two new subgroups that are deﬁned by splitting in split point k of variable Zj. The
split point is then chosen as follows:
k ¼ argmin
k
cðtkj,kj,kjÞ
Appendix 3
Empirical evaluation
To check whether the proposed method can recover smooth treatment eﬀect functions, we evaluated its
performance on artiﬁcial data. To do so, we simulated data from a normal linear regression model. We
simulated 10 correlated patient characteristics, where only one is in a non-linear interaction with the treatment.
In the following, we compare the log-likelihood of our method to the log-likelihood of the true underlying model
and the naive model that assumes an overall applicable treatment eﬀect (Appendix 3.1) and show the predicted
treatment eﬀects in dependence plots (Appendix 3.2) and the variable importances of the true predictive factor and
the noise variables (Appendix 3.3).
We simulated 600 patients, half of which were treated (xA¼ 1) and half of which were untreated (xA¼ 0). The 10
partitioning variables Z are normally distributed
Z 	 N 10ð0, ZÞ ð19Þ
and correlated with the covariance matrix
X
Z
¼
1 0:2    0:2
0:2 1    0:2
..
. ..
. . .
. ..
.
0:2 0:2    1
0BBBB@
1CCCCA
The primary outcome depends on treatment and partitioning variables as follows:
YjX ¼ x,Z ¼ z 	 Nð1:9þ 0:2  xA þ 3  cosðz1Þ  xA, 1Þ ð20Þ
In this example, the true model parameters are deﬁned as follows:
ðzÞ ¼ 1:9
ðzÞ ¼ 0:2þ 0:3  cosðz1Þ
ð21Þ
This means that the treatment eﬀect depends on the value of z1 and this dependency has the form of a cosine
function (see Figure 9).
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3.1 Comparison of models by comparing the log-likelihood
To compare our method with (a) a correctly speciﬁed model taking into account the main eﬀects of xA and cosðz1Þ
as well as the interaction of xA and cosðz1Þ and (b) a simple linear model including only the treatment xA as a
covariate, we drew 100 learning samples and 100 test samples using the data simulation procedure explained above
and computed the out-of-sample log-likelihoods (i.e. based on the test data) for the models after applying them to
each of the 100 learning data sets. The log-likelihood contributions
‘ ð y, xÞi,b#ðziÞ  ¼ yi  x>i b#ðziÞ 2 ð22Þ
with xi ¼ ð1, xiAÞ> and b#ðziÞ ¼ ð^ðziÞ, ^ðziÞÞ> are taken from the personalised models of our method (see
Section 2.5). Note that for the simple linear model the log-likelihood contributions are deﬁned as above,
but only with constant parameters, for the fully speciﬁed model xi ¼ ð1, xA, cosðz1Þ, xA  cosðz1ÞÞ> and
#^ ¼ ð^, ^A, ^cosðz1Þ, ^A, cosðz1ÞÞ>.
The log-likelihoods of our method are higher than the log-likelihoods of the simple and incorrect linear model
and lower than the log-likelihoods of the correctly speciﬁed model (Figure 10). Therefore, we conclude that our
method performs reasonably well.
3.2 Dependence plots
For the same 100 simulated test data sets as above, we obtained the dependence plots. Figure 11 shows two
dependence plots in which all 100 simulations are combined by layering them on top of each other. The
dependence plot of partitioning variable z1 (Figure 11(a)) shows a curve that is fairly similar to that of Figure
9, except that the eﬀect is shrunken towards 0. Note that with a larger sample or diﬀerently tuned parameters (e.g.
larger trees), one could get better results for the extreme treatment eﬀects. As expected, for partitioning variables z2
to z10, there is only random ﬂuctuation around 0 (see as an example Figure 11(b), which shows the dependence plot
for z2).
3.3 Variable importance
Variable importances for one simulated data set are shown in Figure 12. As expected, partitioning variable z1 is the
only variable with a clearly positive variable importance. Even though all partitioning variables are correlated, the
method was able to distinguish between the correlation and predictive eﬀect.
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Figure 9. True treatment effect in given simulated data.
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3.4 Comparison to regular forest
Using the same simulated data sets, we compared the personalised models to the output of a conditional inference
forest, a random forest of conditional inference trees.19,39 For the random forest, we computed the treatment eﬀect
for each patient by:
^ðziÞ ¼ y^ð1Þi  y^ð0Þi ð23Þ
where y^
ð1Þ
i is the predicted outcome when patient i is treated, i.e. xAi¼ 1, and y^ð0Þi is the predicted outcome when
patient i is not treated, i.e. xAi¼ 0. This is a common strategy and used, for example, in the ﬁrst step of the Virtual
Twins algorithm.40 Note that equation (23) can only be interpreted as personalised treatment eﬀect for continuous
Figure 10. Out-of-sample log-likelihoods obtained from the three models. Each line represents one simulated data set.
Figure 11. Joint dependence plots of all 100 simulations. (a) Dependence plot for z1. (b) Dependence plot for z2.
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Figure 12. Variable importances of the predictive factor z1 and noise variables z2 to z10.
Figure 13. Mean-squared error between true treatment effect and estimates. Comparison of personalised models and conditional
inference forest (without and with treatment patient characteristics interactions). (a) Dependence plot for z1 with PðAÞ ¼ f ðz1Þ. (b)
Dependence plot for z2 with PðAÞ ¼ f ðz1Þ. (c) Dependence plot for z1 with PðAÞ ¼ 1 f ðz1Þ. (d) Dependence plot for z2 with
PðAÞ ¼ 1 f ðz1Þ. (e) Dependence plot for z1 with PðAÞ ¼ f ðz2Þ. (f) Dependence plot for z2 with PðAÞ ¼ f ðz2Þ. (g) Dependence plot
for z1 with PðAÞ ¼ 1 f ðz2Þ. (h) Dependence plot for z2 with PðAÞ ¼ 1 f ðz2Þ.
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outcomes. In all other situations, a model-based approach allowing a clear treatment eﬀect parameter to be
included is mandatory.
We looked at two versions of the random forest: One, where we include all patient characteristics and the
treatment indicator as split variables (cforest 1) and one, where we additionally include the interaction terms
between each patient characteristic and the treatment indicator (cforest 2), i.e. xA  zj (j ¼ 1, . . . , 10).
Figure 14. Joint dependence plots of all 100 simulations. (a) Dependence plot for z1 with P(A) = f(z1). (b) Dependence plot for z2
with P(A) = f(z1). (c) Dependence plot for z1 with P(A) = 1 – f(z1). (d) Dependence plot for z2 with P(A) = 1 – f(z1). (e) Dependence
plot for z1 with P(A) = f(z2). (f) Dependence plot for z2 with P(A) = f(z2). (g) Dependence plot for z1 with P(A) = 1 – f(z2). (h)
Dependence plot for z2 with P(A) = 1 – f(z2).
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The distribution of mean-squared error (MSE) between the true treatment eﬀect and the estimates for the 100
simulated data sets is shown in Figure 13. The personalised models outperform the random forests on almost all
data sets generated. The inclusion of the interaction as split variable does not improve the random forest, which
can be expected as random forests are good at ﬁnding interactions by design. The average MSE over 100
simulations is 1.99 for the personalised models, 2.51 for the ﬁrst version of the random forest and 2.54 for the
second version.
Appendix 4
Impact of non-randomised treatment
Even though the personalised models were developed for the application in randomised clinical trials, we
acknowledge that randomisation is not always possible and the interest for methods that can be used in
observational studies is high. Here, we investigated the behaviour of the method when the treatment
assignment depends on a patient characteristic. We simulated data similar to Appendix 3, but instead of a
cosine function we now use the logistic function
YjX ¼ x,Z ¼ z 	 Nð1:9þ 0:2  xA þ 3  f ðz1Þ  xA, 1Þ ð24Þ
with
f ðzÞ ¼ 1
1þ expð1:5  zÞ ð25Þ
and the treatment assignment is not randomised but depends on a patient characteristic. We consider four
scenarios for the probability of receiving treatment A:
PðxA ¼ 1jZ ¼ zÞ ¼
f ðz1Þ scenario 1
1 f ðz1Þ scenario 2
f ðz2Þ scenario 3
1 f ðz2Þ scenario 4
8>>><>>>: ð26Þ
In scenarios 1 and 2, the prognostic factor z1 inﬂuences the probability of being treated with treatment A. In
scenarios 2 and 3 z2, a patient characteristic with no inﬂuence on the outcome, inﬂuences the probability of being
treated with treatment A. Dependence plots are shown in Figure 14. Scenarios 1 and 2 lead to a bias in the
estimation of the treatment eﬀect (Figure 14(a) to (d)), but for scenarios 3 and 4, there does not seem to be a
problem. Therefore, in the cases where the patient characteristic that inﬂuences the treatment assignment is not a
predictive factor, this simple simulation study reveals no problems.
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Abstract
Model-based trees are used to find subgroups in data which differ with respect to model
parameters. In some applications it is natural to keep some parameters fixed globally for
all observations while asking if and how other parameters vary across subgroups. Existing
implementations of model-based trees can only deal with the scenario where all parameters
depend on the subgroups. We propose partially additive linear model trees (PALM trees)
as an extension of (generalised) linear model trees (LM and GLM trees, respectively), in
which the model parameters are specified a priori to be estimated either globally from
all observations or locally from the observations within the subgroups determined by
the tree. Simulations show that the method has high power for detecting subgroups in
the presence of global effects and reliably recovers the true parameters. Furthermore,
treatment-subgroup differences are detected in an empirical application of the method to
data from a mathematics exam: the PALM tree is able to detect a small subgroup of
students that had a disadvantage in an exam with two versions while adjusting for overall
ability effects.
Keywords: subgroup analysis, model-based recursive partitioning, GLM, tree.
1. Introduction
Model-based recursive partitioning (Zeileis, Hothorn, and Hornik 2008) is used to partition
data into groups that differ in terms of the parameters in the model. The method can be
applied, for example, to find subgroups in a clinical trial which differ in terms of treatment
effect on a health score (e.g. Seibold, Zeileis, and Hothorn 2016) or areas in a city which differ
in terms of the influence of square metres on the rent price. Sometimes there are parameters in
the model that one wants to fix for all groups, e.g. the effect of smoking on the health outcome
in the clinical trial or the effect of inflation/deflation on rent prices. This, however, is not
possible in model-based recursive partitioning as described in Zeileis et al (2008). Here we
propose an algorithm called PALM tree that is similar to model-based recursive partitioning
but allows fixing parameters over all groups, i.e. only some parameters depend on the tree
structure.
There have been several developments in the past years toward the direction of combining
models and trees, where one part of the model follows a tree structure and one part does
not. The Simultaneous Threshold Interaction Modeling Algorithm (STIMA, Dusseldorp,
Conversano, and Van Os 2010) starts off with a main effects model and adds interactions
This is a preprint of an article accepted for publication in Advances in Data Analysis and
Classification, doi:10.1007/s11634-018-0342-1.
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2 Generalised Linear Model Trees with Global Additive Effects
based on a tree. Fokkema, Smits, Zeileis, Hothorn, and Kelderman (2017) proposed GLMM
tree, a method that is similar to PALM tree, but is used to fix random effects in a generalised
linear mixed-effects model (GLMM) instead of – as in PALM tree – further fixed effects.
Other approaches going in the direction of GLMM tree are RE-EM tree (Sela and Simonoff
2012) and MERT (Hajjem, Bellavance, and Larocque 2011).
In the literature on subgroup analyses for the estimation of treatment effects, special tree-
based procedures have been proposed (see, e.g. Doove, Dusseldorp, Van Deun, and Van Meche-
len 2014). These methods are commonly used in the analysis of clinical trials, but are equally
relevant in contexts such as marketing studies evaluating different marketing strategies or
studies on website user behaviour, where users are randomly served one of two website ver-
sions (A/B testing). Sies and Van Mechelen (2017) review some of the methods in a setting
where there are some model covariates with fixed parameters across all subgroups and varying
treamtent effect. One promising method in this review is a method by Zhang, Tsiatis, Da-
vidian, Zhang, and Laber (2012) which estimates rules of optimal treatment for each patient
subgroup (optimal treatment regimes).
The following sections unfold as follows: In Section 2 we will first describe GLMs and GLM
trees as the basics needed for PALM trees and then go into how PALM trees are computed.
Furthermore we will show how model-based trees (LM trees, GLM trees and PALM trees)
can be used for finding subgroups with differential treatment effects. In Section 3 we will
show the results of a simulation study in which we compare LM tree, PALM tree, STIMA
and the optimal treatment regime method by Zhang et al (2012). In Section 4 we will apply
the PALM tree to data of a mathematics exam, where the endpoint is performance in the
exam, the “treatment” is the student group (early morning or late group) and the known
prognostic factor is the performance in online tests the students participate in during the
semester. Finally we will discuss strengths and limitations of model-based trees in general
and PALM trees in particular.
2. Methods
In this section we first describe the basics needed for PALM trees – GLMs and GLM trees –
and then introduce PALM trees and how GLMs and GLM trees are used in the PALM tree
algorithm. We focus on GLMs since LMs are a special case of GLMs.
2.1. Basics: GLMs and GLM trees
GLMs
GLMs model the expected response µ = E(y) given the covariates x. To fix notation we write
the GLM as g(µ) = x>β where g denotes the link function and x>β the linear predictor with
coefficient vector β. The coefficients are estimated by maximising the log-likelihood. The
observation-wise log-likelihood contributions are denoted by l((y,x)i,β) with i = 1, . . . , n
indexing the i-th observation and l is defined depending on the appropriate exponential family
chosen for the GLM (Gaussian, Poisson, etc.).
In the following we will make use of two refinements commonly used in GLMs: (a) interac-
tions and (b) offsets. Interactions are effects combinding two or more covariates and can be
Copyright© 2018 Springer-Verlag
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z1
≤ 0 > 0
β1
z2
≤ 0 > 0
β2 β3
Figure 1: Example of a model-based tree.
employed to establish subgroup-specific coefficient vectors in a single model:
g(µ) = x˜>β˜ = I(subgroup1) · x>β1 + I(subgroup2) · x>β2 + . . . (1)
where I(subgroupj) equals 1 for observations in the j-th subgroup and 0 for others. The
combined coefficient vector is simply β˜ = β>1 ,β
>
2 , . . . )
>
Offsets in GLMs are useful for incorporating additional terms whose effects are known or fixed
into the linear predictor :
g(µ) = x>β + offset. (2)
Thus, the offset behaves like an additional regressor whose coefficient is not estimated but
fixed, e.g. to 1. A prominent example for offsets in GLMs is the modeling of rates in Poisson
regression, where offset = 1 · log(exposure).
GLM trees
Tree algorithms generally split the data recursively into disjoint subgroups (also called nodes)
starting from the so-called root node containing all data and employing certain split points in
the so-called split variables. In case of GLM trees, the idea is to (1) estimate the parameters
in a GLM using the current sample (starting with the full data set), (2) assess whether the
parameters are stable over the split variables considered, (3) split the sample along the variable
associated with the highest parameter instability, (4) repeat the previous steps recursively until
some stopping criterion is met (e.g., with respect to the size of the sample or the instability
of the parameters). Various algorithms have been suggested that can be employed for such
GLM-based recursive partitioning, including GUIDE (Loh 2002), CTree (Hothorn, Hornik,
and Zeileis 2006), or MOB (Zeileis et al 2008) where the latter is used subsequently and
explained in more detail in Section 2.2.1.
Copyright© 2018 Springer-Verlag
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Figure 1 shows an example tree structure that could be found by a GLM tree with
β(z) =

β1 if z1 ≤ 0
β2 if (z1 > 0) ∧ (z2 ≤ 0)
β3 if (z1 > 0) ∧ (z2 > 0).
(3)
The parameters β1, β2, and β3 can be estimated by three separate models for the three
subgroups or by using interaction terms as in Equation 1 (I(subgroup1) = I(z1 ≤ 0) etc.).
To make the role of the split variables more explicit we from now on write x>β(z) instead
of x˜>β˜. β(z) is the interaction effect between covariates x and the subgroups defined by the
split variables z.
2.2. Extension: PALM trees
GLM trees assume that all parameters are subgroup specific. This does not necessarily have
to be the case. PALM trees address this issue and offer a compromise between GLM trees
and GLMs by having one part in which the parameters depend on subgroups (these are
again denoted by β(z)) and another part in which the parameters are the same for all sub-
jects/subgroups (denoted by γ).
Going from GLMs via GLM trees to PALM trees can be viewed as an evolutionary process
where one method evolves from the other. The goal of all three is to appropriately estimate
the effect of covariates x on an outcome y. The main difference between the three methods is
the structure of the linear predictor. While the effects β are linear in a GLM, the effects β(z)
are linear and constant within each subgroup but vary between subgroups, i.e. are subgroup-
wise linear. A PALM tree contains globally fixed linear effects γ for some covariates xF and
subgroup-wise varying linear effects β(z) for other covariates xV . Mathematically this can
be expressed as follows:
GLM g(µ) = x>β (4)
GLM tree g(µ) = x>β(z) (5)
PALM tree g(µ) = x>V β(z) + x
>
Fγ. (6)
In PALM trees the variables xF with a global effect γ have to be defined a priori. Usually xV
and xF and z do not overlap although this is, in principle, possible. Note that if the subgroup
structure were known, models 5 and 6 could both be estimated as GLMs. Only the fact that
it is unknown and has to be detected makes GLM trees and PALM trees necessary. Also, if
the global parameter vector γ were known, model 6 could be estimated as GLM tree with
x>Fγ as offset (as in equation 2). These connections between the methods are leveraged in
the PALM tree algorithm.
Algorithm
We now describe the detailed GLM tree and PALM tree algorithms, starting with GLM
trees as the PALM tree algorithm uses GLM trees in the estimation process. The GLM tree
algorithm is not new and has been explained in depth by Zeileis et al (2008). The following
description of the algorithm focuses on the parts that are necessary in order to demonstrate the
full concept of the PALM tree algorithm. Note that to notationally distinguish the parameters
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in the subgroups (e.g. parameter vector in first subgroup β1) from parameters in the models
(e.g. first model parameter β(1)) we use parentheses. GLM trees are grown as follows, starting
with the root node containing all observations:
1. Compute model (4), or equivalently model (5) with a single subgroup (β(z) = β), in
the given node.
2. Test for instability in the model parameters with respect to each of the possible subgroup
defining variables Z1, . . . , ZJ :
• Compute the score contributions
s(k)
(
(y,x)i, βˆ
)
=
∂l ((y,x)i,β)
∂β(k)
∣∣∣∣
βˆ
as the partial derivatives of the log-likelihood contributions of each observation i
(i = 1, . . . , n) with respect to the model parameters β(1), . . . , β(K) evaluated at the
estimated parameters βˆ = (βˆ(1), . . . , βˆ(K))
>.
• Test if the scores fluctuate randomly around zero for each variable Zj (j = 1, . . . , J)
, i.e.
H
β(k),j
0 : S(k)
(
(Y,X), βˆ
)
⊥ Zj
using M-fluctuation tests (Zeileis and Hornik 2007).
3. If the overall test is significant (usually multiplicity adjustment using Bonferroni cor-
rection is used here), choose variable Zj corresponding to the lowest p-value as the split
variable. In the following, we will use 5% as the global significance level.
4. Choose as split point the point in the split variable which maximizes the sum of likeli-
hoods in the emerging subgroups.
5. Iterate steps 1 to 4 until H
β(k),j
0 ∀k, j cannot be rejected or some other stop criterion
(e.g. minimum subgroup size is reached) is fulfilled.
The resulting groups differ with respect to at least one of the model parameters β. In practice,
however, all parameters vary slightly between subgroups due to the refitting of the model in
each node, i.e. for each group of observed subjects. If in reality some covariates influence the
response linearly (for all observations), this leads to an overly complex model. The PALM
tree algorithm eliminates this downside by introducing the possibility to build models where
some parameters are kept stable across subgroups. This is achieved by starting the estimation
of model (6) with a single subgroup, i.e. β(z) = β, and then iterating the tree growing process
between
(a) estimating γ for a given tree structure and
(b) estimating the tree structure for a given γˆ (steps 1.-5.).
In (a) we estimate the full model (6) for the known subgroup × covariate (xV ) interactions
(as in equation 1) and get estimates for β˜ and γ. In (b) we treat the estimated γˆ as fixed and
include x>V γˆ in the model as an offset. By preventing γ from being estimated, we exclude it
Copyright© 2018 Springer-Verlag
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from the score function and can grow a standard GLM tree (as in steps 1.-5.) for the remaining
parameters. At the same time we want to account for the effects of xV which is obtained by
including x>V γˆ as offset. The iterative process stops when no (or very little) improvement in
terms of log-likelihood can be achieved (typically when the tree structure does not change
anymore). Iterating between (a) and (b) simplifies estimation by only having one unknown:
either γ or the tree structure. β(z) is estimated in both steps: In (a) by estimating the model
with the known subgroup × covariate interactions, and in (b) by estimating a separate model
for each subgroup.
PALM trees inherit many of their theoretical properties from the methods used as building
blocks (model-based trees and parametric models), provided that the model is well specified:
Given that the group structure is correctly detected by the tree, the (G)LM can consistently
estimate all coefficients (grouped and global). Conversely, given that the global coefficients
are estimated consistently, the (G)LM tree uses a group detection based on locally consistent
tests (Zeileis and Hornik 2007) and the usual locally optimal greedy forward selection in
recursive partitioning (see e.g. Breiman, Friedman, Stone, and Olshen 1984). To the best of
our knowledge, there is no formal proof that alternating between (a) and (b) will converge
to an “optimal” solution so that the strengths of both components are guaranteed to be
effective. However, our simulation results (see Section 3 and Appendix A) show that PALM
trees typically converge quickly and reliably. This was also found for RE-EM trees (Sela
and Simonoff 2012). While there is no guarantee that this is always the case, we have not
experienced any convergence issues thus far.
2.3. Special application: Treatment effects
One common application of model-based trees is for subgroup analyses in clinical trials (Lip-
kovich, Dmitrienko, and D’Agostino 2016; Seibold et al 2016; Doove et al 2014). In the
simplest case one is interested in a treatment effect of a new treatment versus standard of
care or no treatment, i.e. x or xV = (1, xA) with xAi = I(patient i received new treatment).
In this setting one differentiates between prognostic and predictive factors (Italiano 2011).
Prognostic factors are patient characteristics (measured before treatment start) which di-
rectly impact the response, e.g. a health score. Predictive factors are patient characteristics
which impact the efficacy of the treatment. In the PALM tree framework, predictive factors
should be included in the split variables z and prognostic factors, if known in advance, can
be included in xF . In fact, prognostic factors are often known in advance based on previous
research about the disease.
In subgroup analyses for treatment effects the term optimal treatment regime is commonly
mentioned. An optimal treatment regime is a rule which indicates which treatment is better
in which subgroup. Treatment regimes only check the sign of the treatment effect in each
subgroup. If they differ between subgroups, the treatment effects are called qualitative; if one
treatment is better than the other in all subgroups, they are called quantitative. As this
application is very common, the remainder of this manuscript will deal with scenarios where
the partitionable parameters are the intercept and the effect of a binary covariate.
2.4. Comparison to other approaches
GLMM trees (Fokkema et al 2017) are closely related to PALM trees, as the algorithm also
builds on the GLM tree algorithm and like PALM tree keeps parts of the model stable. The
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major difference is the fact that GLMM trees focus, as the name says, on generalised mixed
effects models and the part that is being kept stable across subgroups are the random effects.
STIMA (Dusseldorp et al 2010) is a tree algorithm where the first split is made in an a priori
specified variable, which in the treatment case is the treatment indicator. All further splits are
found by an exhaustive search and finally a cross-validation based pruning procedure is run
to find the optimal tree. STIMA is similar to PALM tree in the sense that it starts off with
a main effects model and new splits are selected based on a measure of variance-accounted-
for. The main effects of the model are kept stable across groups and additional effects are
added to the model based on the tree structure. A very similar approach is called partially
linear tree-based regression model (PLTR, Chen, Yu, Hsing, and Therneau 2007; Mbogning
and Toussile 2015), which was initially invented to analyse gene-gene and gene-environment
effects.
The approach by Zhang et al (2012) aims to estimate optimal treatment regimes and is only
used in the treatment effect application. In the following we will use the term OTR (optimal
treatment regimes) for this method. OTR is not as closely related to PALM tree as the
previously mentioned methods, but has shown good performance in settings in which PALM
trees are appropriate (Sies and Van Mechelen 2017). OTR does not target estimating the
treatment effect itself but targets learning which treatment is superior for certain groups of
patients. OTR starts off with the so-called outcome model, which includes main effects and
treatment × patient characteristics interactions. After estimating the model the algorithm
proceeds as follows:
1. For all patients in the training data predict the response under treatment µˆ1 and under
control µˆ0 from the outcome model. Determine the difference µˆ1− µˆ0 between the two.
2. Compute a classification algorithm using I(µˆ1 − µˆ0 > 0) as response and |µˆ1 − µˆ0| as
weights.
Any classification method that can deal with (non-integer) weights could be used in step 2.
For further tree-based approaches that allow doing analyses similar to model-based trees see
Doove et al (2014).
3. Simulation study
We compare the performance of PALM trees, LM trees, the trees grown based on the algorithm
proposed by Zhang et al (2012) (OTR) and STIMA in the treatment effect setting. We
chose OTR as competitor because it showed good perfomance in scenarios where PALM
trees should perform well (Sies and Van Mechelen 2017) and we chose STIMA because it
is a natural competitor due to the similarity of the resulting model. Note that while the
setup of the simulation study is motivated by treatment effect studies, the insights are of
broader interest due to its general structure. The aim is to evaluate the methods with
respect to (1) finding the correct subgroups (Section 3.1), (2) not splitting when there are
no subgroups (Section 3.2), (3) finding the optimal treatment regime (Section 3.3), and (4)
correctly estimating the treatment effect (Section 3.4). Note that evaluations (1) and (2)
are connected in the sense that they both evaluate the ability to find the correct subgroups.
Furthermore, (3) and (4) are connected in the sense that both evaluate the ability to give
good treatment recommendations.
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Simulation variable Default Variation # Values
Difference in treatment effects ∆β 0.5 0.1–1.5 8
Number of observations n 300 100–900 5
Qualitative treatment × subgroup interaction Yes Yes/No 2
Number of patient characteristics m 30 10–70 4
Number of predictive factors p 2 1–4, 0 4, 1
Number of prognostic factors q 2 1–4 4
Table 1: Simulation settings. For each scenario one simulation variable is varied and the rest
are kept to the standard value. The value p = 0 is only used for the assessment of the type 1
error rate (Section 3.2).
We simulate a binary variable (treatment indicator) XA which is either 1 or 0, each with
probability 0.5, and m correlated variables (patient characteristics)
Z ∼ Nm(0,Σ) (7)
with
Σ =

1 0.2 · · · 0.2
0.2 1 · · · 0.2
...
...
. . .
...
0.2 0.2 · · · 1
 . (8)
We define the first p variables Z1, . . . , Zp to be the true predictive factors, i.e. the patient
characteristics that actually interact with the treatment and thus pose relevant split variables.
The cutpoint is always at Zj = 0 and the subsequent split is always in the subgroup with Zj >
0, i.e. on the right side of the tree when visualised as in Figure 1. We define the consecutive
q variables XF = (Zp+1, . . . , Zp+q) to be the true and known prognostic factors. All further
patient characteristics Zp+q+1, . . . , Zm are noise variables. We simulate the outcome variable
Y with
Y = XAβ(Z) +XFγ + U (9)
where U ∼ N (0, 1.5) is the error term.
The effect of the prognostic factors is set to γ = 1. The treatment effect β(Z) follows a tree
structure, which is visualised in Figure 1 for the scenarios with p = 2. The mathematical
representation is as in Equation (3) with a fixed difference between the effects in the subgroups
∆β. We define a default simulation scenario, which is shown in the second column of Table 1.
In this default scenario ∆β = 0.5 and
β(Z) =

−0.375 = β1 if Z1 ≤ 0
0.125 = β2 = β1 + ∆β if Z1 > 0 ∧ Z2 ≤ 0
0.625 = β3 = β2 + ∆β if Z1 > 0 ∧ Z2 > 0.
(10)
To obtain a diverse set of simulation scenarios which are comparable, we fix all but one of
the simulation variables to the default. The range of variation of each simulation variable is
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given in the third column of Table 1 alongside the number of equidistant values considered
(# Values). From this we get all necessary information about the simulation, e.g. q takes 4
different values 1, 2, 3, 4. For each distinct simulation setting we simulate 150 data sets. Note
that just for the assessment of the type 1 error rate (Section 3.2) the number of predictive
factors is set to zero. For the simulation scenarios where p 6= 2 and thus less/more than three
true subgroups exist, β(Z) follows the same logic as in Equation (10), i.e. βb = βb−1 + ∆β
for b = 2, . . . , (p+ 1). The value of β1 depends on whether the first split is qualitative or not
and on ∆β. If the first split is not qualitative then β(1) = 0.5. If the first split is qualitative
β(1) = −3/4 ·∆β. This also means that any consecutive splits after the first are quantitative.
This simulation study is limited due to the fact that we only change one simulation variable
at a time. Section A in the Appendix shows selected results from a full factorial simulation
study. Using the simulated data we compare the following methods:
PALM tree with xV = (1,xA) and xF = (zp+1, . . . , zp+q). The only way we could have
specified this algorithm better for the given data generating process would have been to
add the intercept to xF , but in real application one would usually allow the intercept
to vary to account for unknown prognostic factors contained in z.
LM tree 1 with x = (1,xA). This algorithm is of interest to see how well a misspecified
model-based tree behaves. LM tree 1 has to approximate x>Fγ using step functions and
thus cannot give good results in terms of most measures used below. However, we are
interested in how well it can do in terms of estimating the correct treatment regime.
LM tree 2 with x = (1,xA,xF ). This tree is expected to behave better than LM tree 1,
since it contains the correct covariates in the model, but worse than PALM tree since it
may split with respect to instabilities in the parameters for xF plus it is overly complex
due to the fitting of separate xF -parameters in each subgroup.
OTR with outcome model g(µ) = (1,xA,xF )
>γ + (xA : z)>β (with xA : z interaction
between xA and z) and pruned CARTs (Classification and Regression Trees, Breiman
et al 1984) as classification method. OTR was invented to find optimal treatment
regimes and thus is expected to be good at finding the right treatment. OTR is not
intended to find quantitative interactions and thus can not be good at this.
STIMA with a forced first split in the treatment and the maximum number of splits fixed
to six.
3.1. Are the correct subgroups found?
To investigate whether the correct subgroups are captured by the different methods, we looked
at the number of subgroups found as well as the adjusted Rand index (ARI, Hubert and Arabie
1985; Milligan and Cooper 1986). The ARI measures how well the retrieved subgroups fit with
the true underlying subgroups. If the subgroups found are similar to the true subgroups the
ARI will have a value up to 1. If the subgroups are only as good as a random group assignment
the ARI is 0. If there is systematic missclassification, the ARI can also be negative.
The first row of Figure 2 shows the mean number of selected subgroups over the 150 simulated
data sets and their corresponding trees for differing distances between treatment effects ∆β
and differing numbers of observations n. This means we are looking at the case where all
Copyright© 2018 Springer-Verlag
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Figure 2: Mean number of subgroups and mean ARI for varying ∆β and number of observa-
tions (Question 3.1).
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Figure 3: Mean number of subgroups for varying types of subgroups (quantita-
tive/qualitative), number of patient characteristics, predictive factors and prognostic factors
(Question 3.1).
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variables are kept at the standard value except ∆β or n respectively. The second row shows
the corresponding ARI. The similarity between the PALM tree and LM tree 2 algorithms is
obvious. For both the number of subgroups and the ARI the results are very similar, although
PALM tree is slightly better. Both algorithms get steadily closer to the optimal solution with
increasing ∆β as well as with increasing number of observations. LM tree 1 performs badly
because it approximates the linear relation between the prognostic factors and the response
with splits in the data. This is also the reason why with increasing n the number of subgroups
increases. This effect muﬄes the grouping with respect to the treatment effect, even if it gets
less with increasing ∆β. The number of subgroups found for OTR is on average greater than
the actual number of subgroups (3 for the given scenarios in Figure 2). The variability of
the number of subgroups for OTR is very high (with a maximum of 20 subgroups). The true
subgroups are not captured as well as with PALM tree and LM tree 2. The ARI for OTR
is lower than the ARI of PALM tree and LM tree 2 except for very low values of ∆β and n,
which can be explained by the fact that the model-based trees use statistical significance tests
and CART does not. Even though the pattern of STIMA in terms of the average number of
subgroups appears similar to PALM tree and LM tree 2, on average the ARI is considerably
lower, except for very large differences in treatment effects (∆β).
Figure 3 shows the mean number of subgroups for the remaining simulation scenarios. The
model-based trees and STIMA are not affected by the type of subgroup. OTR, however, is
designed to find only qualitative subgroups and thus on average finds fewer groups when there
are only quantitatively differing subgroups. For increasing number of patient characteristics,
the model-based trees become more conservative and find slightly less subgroups, which is due
to the correction for multiple testing (Bonferroni correction). OTR and STIMA do not change
much in terms of average number of subgroups when the number of patient characteristics
increases. With increasing number of predictive factors the number of subgroups should
increase. The true number of subgroups is always the number of predictive factors + 1. The
lower left panel of Figure 3 shows that this is not the case for any of the algorithms. The
reason for this is the way of how we simulated the data. With an increasing number of
predictive factors the subgroups get smaller and thus there is less power to find splits. The
only algorithm that is strongly affected by the number of prognostic factors is LM tree 1,
which corresponds to the fact that there are more linear terms to approximate through the
tree structure.
3.2. How often are subgroups found even though there are none?
To investigate the type 1 error rate, i.e. the probability that subgroups are found even though
there are none, we simulated data as above, but with no predictive factors. This means the
treatment effect is the same for all patients. Figure 4 shows the behaviour of the methods with
changing number of observations. LM tree 1 and OTR have a constant value of 1 here and
are not visualised. Since LM tree 1 finds subgroups that have to do with the prognostic factors
the “bad” performace exists by design. PALM tree is close to the expected 5% significance
level, as is LM tree 2. STIMA goes down to 0% for 700 and 900 observations.
3.3. Is the correct treatment predicted to be better?
The next measure we wanted to look at is the proportion of patients for which the better
treatment is correctly identified. This is what OTR was designed to be good at and especially
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Figure 4: Proportion of trees with more than one subgroup for varying number of observations
(Question 3.2). Black line at 0.05.
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Figure 5: Proportion of observations in all trees where better treatment is correctly identified
(Question 3.3).
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Figure 6: Mean absolute difference between true and estimated treatment effect (mean abso-
lute error, MAE; Question 3.4).
due to the way we simulated data (with a simple interaction) OTR can be expected to perform
well. Figure 5 shows the proportion of patients for which the better treatment is correctly
identified for the scenarios with varying difference between treatment effects ∆β and varying
number of predictive factors. When the difference between treatment effects ∆β is small it is
difficult for all methods to predict the correct treatment regime. For ∆β = 0.1 it is close to
random guessing. With increasing ∆β all methods get better. The performance of PALM
tree, LM tree 2, OTR and STIMA is similar. The four methods also behave similarly with a
changing number of predictive factors. The treatment regime prediction is globally worst on
average when there is one predictive factor. This results from the fact that often no split is
found in this case (see Figure 3). In cases where the methods decide not to split at all, this
leads by simulation design to a proportion of 50% correctly-defined treatment regimes. The
proportion of patients for which the correct treatment is predicted to be the better treatment
improves in cases of two or three predictive factors and gets worse with four predictive factors.
With more complex and smaller subgroups it becomes more difficult for the algorithms to
retrieve the correct subgroup structure and to estimate the treatment effect. Note, however,
that shape of the shape of the curves in the right panel of Figure 5 is very specific for the
simulation settings here. Figure 9 shows the results for other scenarios. For example, for
∆β = 1.5 and 300 observations in a setting with qualitative treatment differences, the best
performace of PALM tree is with only one predictive factor and decreases from there. The
performance of all algorithms is well in quantitative settings. OTR is the only algorithm that
goes down to only 80% correctly defined treatment regimes in settings with 100 observations.
3.4. How good is the treatment effect estimate?
Estimating or even predicting the correct treatment effect is the most essential part of sub-
group analysis. Even if one treatment is better than the other, clinicians need to know if the
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difference is relevant. The evaluation of the treatment effect estimate can only be done for
the model-based recursive partitioning methods and STIMA since OTR is only designed to
produce binary decision rules. The measure used to evaluate the treatment effect estimate
is the mean absolute difference between true and estimated treatment effect (mean absolute
error, MAE). Figure 6 shows the MAE for the scenarios of varying ∆β and varying number of
predictive factors. The error is smallest for all three methods when the difference in treatment
effect is lowest (∆β = 0.1), because even if the chosen subgroups are wrong, the estimated
treatment effect will likely be close to the true and very similar treatment effects. In this
sense it is not a disadvantage that PALM tree, LM tree 2 and STIMA often do not split into
subgroups at all. In fact, it may even be an advantage, as the treatment effect estimate is
then calculated based on a larger data set and is less affected by random variability. The
effect of the small treatment difference gets less as the difference increases. However, as the it
increases, finding the correct subgroups becomes easier and the error decreases. At the same
time finding the correct subgroups becomes easier and slowly the error decreases again for
PALM tree, LM tree 2 and STIMA. For this effect to be visible for LM tree 1, one would have
to have larger treatment effects, fewer prognostic factors and/or more observations, given
the large effect of the prognostic factor (see Figure 11 in the Appedix). With an increasing
number of predictive factors the mean absolute error in treatment effect increases. The shape
of the curve in Figure 6 looks very different to the one in Figure 5, even though they address
similar questions, but the more true predictive factors exist in the given simulation scenario
the harder it is for the methods to predict the treatment effect. This suggests that simply
knowing the more effective treatment does not tell the whole story. This is supported across
simulation scenarios (compare Figures 9 and 10).
4. Illustration: Treatment differences in mathematics exam
The Mathematics 101 course for first-year business and economics students at Universita¨t
Innsbruck gives an introduction to mathematical analysis, linear algebra, financial mathe-
matics, and probability calculus. Students are assessed by biweekly online tests during the
semester and a written exam at the end. The exam consists of 13 single-choice questions with
5 answer alternatives, one of which is correct. Students who answer more than 60 percent
of the questions correctly pass the course. The percentage of successful online tests captures
math ability of the students and is a known predictor for success in the final exam.
The data contains the exam results of 729 students (out of 941 who originally registered
for the course) for the fall semester in 2014/15. Due to limited availability of seats in the
exam room, the students were asked to select a group, where the first group wrote the exam
in the morning and the second group right after the first group finished. The two groups
received slightly different questions on the same topics covering the scope of the course. We
are interested in whether the exam is fair in the sense that it is on average equally hard or
difficult for the two groups. In other words we want to find out whether there is a “treatment
effect” with the different selection of exam questions in the two groups corresponding to the
“treatments”. As a first rather naive check we consider a simple one-way regression model
for the percentage of correct answers by group, as reported in the first column of Table 2.
This yields an expected percentage of 57.6 for a student in group 1 and a difference of 2.33
percentage points for students in group 2. Thus, the model finds only a small drop in the
percentage of correctly solved answers and the corresponding confidence interval includes a
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zero change.
However, in this first model we have neglected the influence of the students’ ability which is
particularly relevant here because the students could freely choose their exam group. There-
fore, there might have been self-selection of more (or less) able students into the first (or
second) group. To account for such ability effects in the model we include the percentage of
points from the previous online tests that captures the students’ ability and preparation. As
shown in the second column of Table 2 this variable is indeed strongly associated with the
exam results, where one additional percentage point in the online tests leads to additional 0.86
expected percentage points in the written exam. More importantly, the group effect increases
to 4.37 and the corresponding confidence interval does not include zero anymore. Despite
the increase in the group effect, the absolute size of the group difference is still moderate
corresponding to about half an exercise out of 13.
To explore the size of the treatment effect for the group differences further, we consider the
possibility that this may vary across subgroups of students. Known student characteristics
that may lead to such subgroups here are gender, the number of semesters the student has
already been studying, the number of times the student has already attempted the exam,
the type of study (three year bachelor program vs. four year diploma program) and also
the ability/preparation as captured by percentage of successful exercises in the online tests.
Since the test results in the online tests during the semester are known to have an important
direct effect on the performance in the exam, the test parameter is included in the PALM
tree. Figure 7 shows the resulting PALM tree with the segmented local group effect while
adjusting for a global online tests effect. The strongest parameter instability is associated
with the number of attempts and the group of students in the first attempt are split a second
time by the percentage from the online tests. Two of the resulting subgroups (node 3 and 5)
exhibit only very small group differences but in node 4 the second group obtained clearly a
lower response percentage. This node is the smallest subgroup found and encompasses the
highly able students taking the course for the first time. For this subsample the treatment
effect is about 14 percentage points, which means that the students in the second batch solved
about two exercises less than those in the first batch.
Overall this clearly conveys the strength of the PALM tree method: Especially in situations
where the coefficient of interest is modest in a main-effects model and where further covariates
are available whose influence on the main model parameters is not obvious, the PALM tree is
an attractive option to globally control for certain variables while searching for local effects
in others. Note, however, that due to the forward selection of models/effects the resulting
confidence intervals in the terminal nodes (Table 2 and Figure 7) should not be used for
inference but interpreted as a measure of variability.
5. Discussion
Model-based trees are effective tools to identify subgroups in data which differ in terms of
model parameters. PALM trees are special model-based trees where some parameters can
be fixed globally for the entire sample and do not depend on the subgroup structure. Our
simulation study has shown that in cases where there are such specified factors with a direct
effect on the outcome, PALM trees reliably detect the correct subgroups while at the same
time having a low probability of detecting subgroups when there are none. STIMA is a
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Linear model 1
57.60
 [55.12, 60.08](Intercept)
Linear model 2
node3:(Intercept)
PALM tree
node4:(Intercept)
node5:(Intercept)
−2.33
 [−5.70, 1.03]group2
node3:group2
node4:group2
node5:group2
tests
−5.85
 [−13.52, 1.83]
−4.37
 [−7.23, −1.50]
0.86
 [0.76, 0.95]
−7.09
 [−16.15, 1.97]
13.98
 [0.82, 27.14]
2.33
 [−6.32, 10.99]
−3.00
 [−6.97, 0.98]
−14.49
 [−22.92, −6.07]
−1.70
 [−5.97, 2.56]
0.79
 [0.67, 0.90]
Table 2: Three models for the mathematics exam data. The response variable is the percent-
age of correctly solved exercises and the main covariat of interest are the treatment differences
between the first and second exam group. Confidence intervals are given in brackets.
flexible and well performing competitor of model-based trees. The most important downside
of STIMA is that it is very slow with in some instances single trees taking hours to compute
(see Appendix B). Moreover, it has to be taken with a grain of salt that the R package
“stima” is not actively maintained on the Comprehensive R Archive Network. Although
optimal treatment regimes (OTR) perform comparably to PALM trees in terms of detecting
the best treatment option in the given simulation study, PALM trees are typically better
at recovering a parsimonious tree capturing the underlying subgroup structure. This makes
PALM tree results easier to interpret and to communicate to practitioners, which we believe is
an important advantage in many applications. Moreover, the simulation study clearly showed
the effect of misspecifications in global vs. local effects in PALM trees. While it is important
to correctly identify the variables with additive effects (LM tree 1 vs. LM tree 2 or PALM
tree), it is not so important to correctly identify whether these additive effects are global or
local (LM tree 2 vs. PALM tree). However, by reducing the number of tests in the split
procedure and focusing only on certain relevant model parameters, some power and efficiency
can be gained from selecting a suitable PALM tree.
PALM trees allow exploring and questioning results of (generalised) linear models. The PALM
tree analysis of the Mathematics 101 exam showed that a linear model regressing the per-
centage points of correct anwers on the group and earlier test results is too simple. Only
for a relatively small subgroup of students who attempted the exam for the first time and
who showed good performance during the semester it did make a difference whether they
attempted the exam in the first or second group.
Although large parts of this manuscript focus on subgroup analyses in clinical trials, PALM
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Figure 7: PALM tree for the percentage of correct answers explained by group differences
while globally adjusting for ability (i.e., percentage of points obtained in previous online
tests).
trees can also be applied in a wide range of other applications as well – e.g., in the social
sciences as shown in the mathematics exam application case study.
Computational details
Open-source implementations of the model-based tree algorithms LM tree and GLM tree
are available in the partykit package (Hothorn and Zeileis 2015, functions lmtree() and
glmtree()). The PALM tree algorithm is available in the palmtree package (Seibold,
Hothorn, and Zeileis 2017, function palmtree()). OTR is available in package DynTxRegime
(Holloway, Laber, Linn, Zhang, Davidian, and Tsiatis 2015). The STIMA implementation has
been archived on CRAN but can still be downloaded from https://cran.r-project.org/
src/contrib/Archive/stima/. Simulations were conducted using the batchtools package
(Lang, Bischl, and Surmann 2017).
The manuscript including simulation study and application can be reproduced using the
supplementary online material.
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A. Full factorial simulation
The simulation study described in Section 3 takes a ceteris paribus approach and varies
one simulation variable at a time while keeping the others at a standard value. We did an
additional simulation study where we vary all variables, which leads to 8 · 5 · 2 · 4 · 4 · 4 = 5120
(see Table 1) different scenarios. For each scenario we simulated two data sets and ran all
algorithms on each. In the following we show a small selection of interesting graphics based on
the simulations. For the full results of the simulation studies we refer to the online material.
Figure 8 shows the marginal results of the ARI for ∆β, the number of predictive factors, the
number of observations and quantitative versus qualitative interactions. We average over the
Copyright© 2018 Springer-Verlag
- 88 - Paper III
Heidi Seibold, Torsten Hothorn, Achim Zeileis 21
other simulation variables and the two repetitions. For sake of easy visualisation, we restrict
the plotted variable to few levels. Similarly Figures 9 and 10 show the marginal results of the
proportion of correct treatment assignment and mean absolute error in estimated treatment
effect for the number of predictive factors, ∆β, the number of observations and quantitative
versus qualitative interactions. Figure 11 shows the results for the MAE for n = 900 and one
prognostic factor to show when LM tree 1 starts to improve (see Section 3.4).
Figure 8 shows that PALM tree can handle simple subgroups with one predictive factor even
when the number of observations is low, but the difference in treatment effects must be
reasonably high. All other algorithms perform worse, with LM tree 2 and STIMA being the
strongest competitors in the low-n-scenarios. OTR performs reasonably well if qualitative
subgroups are present. For n = 500 the performance of PALM tree rises already at lower
levels of ∆β. The performance of PALM tree and LM tree 2 is very similar and STIMA also
performs well. By design OTR ignores any non-qualitative subgroups.
When quantitative treatment subgroups exist, all methods are good at deciding the correct
treatment regime (see Figure 9), especially when the number of observations is reasonably
high (300). With n = 100 PALM tree, LM tree 2, STIMA and even LM tree 1 still perform
very well. OTR is the weakest competitor here. With low numbers of observations (n = 100),
low treatment effect differences (∆β = 0.5) and qualitative differences, the performance of all
algorithms is close to random guessing (0.5), irrespective of the number of predictive factors.
With higher ∆β PALM tree performs reasonably well, followed by LM tree 2, STIMA and
OTR (order depending on the number of predictive factors). For n = 300 and ∆β = 0.5
STIMA and LM tree 1 perform worst, but STIMA catches up with the other algorithms
when ∆β = 1.5, whereas LM tree 1 stays at the bottom. Section 3.3 discusses these results
in the context of the results in the star-like simulation study.
Section 3.4 already partly discussed Figures 10 and 11. Figure 10 shows that across different
scenarios the MAE increases with increasing number of predictive factors. PALM tree is
among the best performers everywhere. In comparison to the other algorithms it performs
particularly well in low-n-qualitative scenarios whith ∆β = 1.5.
B. Computation times
The computation times for all methods except STIMA are very reasonable in these applica-
tions. For a summary of computation times in the full factorial desing see Table 3. STIMA
reached a maximum of 17.4 hours and almost half the models took half an hour or longer.
Table 3: Quantiles of computation times per algorithm in seconds.
0% 25% 50% 75% 100%
PALM tree 0 0 1 2 7
LM tree 1 0 1 1 2 5
LM tree 2 0 0 1 1 4
OTR 0 0 1 1 2
STIMA 3 233.5 1941 8646.5 62512
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Figure 8: Mean ARI in the full factorial design with two simulated data sets per design
(Question 3.1).
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Figure 9: Proportion of observations in all trees where better treatment is correctly identified
in the full factorial design with two simulated data sets per design (Question 3.3).
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Figure 10: Mean absolute difference between true and estimated treatment effect (mean
absolute error, MAE) in the full factorial design with two simulated data sets per design
(Question 3.4).
Copyright© 2018 Springer-Verlag
- 92 - Paper III
Heidi Seibold, Torsten Hothorn, Achim Zeileis 25
l
l l l l
l l
ll
l
l
l l
l l
l
l
l
l l
l l
l
l
l l
l
l
l
l
0.1
0.2
0.3
0.4
0.1 0.3 0.5 0.7 0.9 1.1 1.3 1.5
∆β
M
AE
(β)
type
PALM tree 
LM tree 1 
LM tree 2 
STIMA
Figure 11: Mean absolute difference between true and estimated treatment effect (mean
absolute error, MAE) in the full factorial design with two simulated data sets per design
(Question 3.4). Limited data to scenarios with 900 observations and one prognostic factor.
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Abstract
Typical models estimating treatment effects assume that the treatment effect is
the same for all individuals. Model-based recursive partitioning allows to relax
this assumption and to estimate stratified treatment effects (model-based trees)
or even personalised treatment effects (model-based forests). With model-based
trees one can compute treatment effects for different strata of individuals. The
strata are found in a data driven fashion and depend on characteristics of the
individuals. Model-based random forests allow for a similarity estimation between
individuals in terms of model parameters (e.g. intercept and treatment effect). The
similarity measure can then be used to estimate personalised models. The R package
model4you implements these stratified and personalised models with a focus on ease
of use and interpretability so that clinicians and other users can take the model they
usually use for the estimation of the average treatment effect and with a few lines
of code get a visualisation that is easy to understand and interpret.
Keywords
personalised medicine; subgroup analysis; model-based recursive partitioning; un-
biased trees; treatment effect; random forest
Introduction
Studies in various fields randomly assign individuals to one of two groups with
different exposure and then measure a response. For example, in clinical trials
patients are assigned to one of two treatment groups where usually one treatment
group receives a new treatment or drug and the other treatment group receives
the standard of care or a placebo. Other examples are in A-B testing in marketing
studies or any other two group comparisons such as the mathematics exam discussed
below, where students were divided into different exam groups and received slightly
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different exam tasks. In the following we will refer to the two groups as treatment
groups and to the group indicator as treatment indicator, which always takes values
0 (individual in first group) and 1 (individual in second group).
Treatment effect estimation is often done using simple models with the binary treat-
ment indicator as only covariate. In the example of a clinical trial the treatment
indicator would be 1 if the patient receives the new treatment and 0 if the patient
receives standard of care. In R such a simple model can be estimated as follows:
base_model <- model(response ~ treatment, data)
with response being the response measured, treatment being the treatment indicator
and data being the data set containing these variables. The function model() can
be replaced for example by lm() to estimate a linear model, glm() to estimate
a generalised linear model or survreg() to estimate a parametric survival model.
These models estimate intercept and treatment effect for all individuals in the data
and allow for predicting the response of other individuals given they do or don’t
receive the treatment of interest.
For cases where the assumption that all individuals have the same intercept and
treatment effect is too strict the R package model4you offers two options:
1. Model-based trees identify subgroups where within the subgroups the model
parameters are similar and between groups the model parameters are different. This
is achieved by finding instabilities in the model parameters with respect to a variable
(characteristicum) and recursively partitioning the data into groups. If, for example
the algorithm finds that men and women have differing treatment effects, the data
is partitioned into two subgroups. Details on model-based trees in general can be
found in [Zeileis et al., 2008] and for the special use case for stratified treatment
effect estimation in [Seibold et al., 2016]. Just a single line of code lets the user
compute a model-based tree in R:
strat_models <- pmtree(base_model)
Note that pmtree() uses the data given in the call of the base model. It automat-
ically uses variables not used in the model formula (in the example above response
~ treatment) as potential subgroup defining variables. This can be edited using the
zformula argument.
2. Personalised models use model-based random forests to estimate similarity
of individuals in terms of model parameters. For each individual a personalised
model can be estimated based on a weighted set of the original data, where the
similarity measure corresponds to the weight. Details on the personalised mod-
els can be found in [Seibold et al., 2017]. Computing personalised models for all
observations in the training data is simple:
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pm_forest <- pmforest(base_model)
pers_models <- pmodel(pm_forest)
Again here the potential effect-modifying variables are taken by default as all vari-
able not given in the model formula and can be defined using the zformula argument
in pmforest().
In the following we will present an example application for model-based trees and
personalised models. For this we need to load the package and – to ensure repro-
ducibility – set a random seed. Also for visualisations we need packages ggplot2,
ggbeeswarm and gridExtra.
library("model4you")
set.seed(2017)
library("ggplot2")
theme_set(theme_classic())
library("ggbeeswarm")
library("gridExtra")
Mathematics exam analysis: In 2014 first-year business and economics stu-
dents at the University of Innsbruck were divided into two examination groups.
Group 1 wrote the exam in the morning and group 2 started after the first group
finished. The exams for the two groups were slightly different. The data can be
accessed and prepared as follows:
data("MathExam14W", package = "psychotools")
## scale points achieved to [0, 100] percent
MathExam14W$tests <- 100 * MathExam14W$tests/26
MathExam14W$pcorrect <- 100 * MathExam14W$nsolved/13
## select variables to be used
MathExam <- MathExam14W[ , c("pcorrect", "group", "tests", "study",
"attempt", "semester", "gender")]
To investigate whether the exam was fair, we asses whether the two groups differ
in terms of the percentage of correctly answered exam questions. This can be done
using a simple linear model regressing the percentage points of correct anwers on
the exam group.
bmod_math <- lm(pcorrect ~ group, data = MathExam)
The estimtates and confidence intervals of this model can be computed via
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Figure 1: Density estimates of base model for the Mathematics Exam data.
cbind(estimate = coef(bmod_math), confint(bmod_math))
## estimate 2.5 % 97.5 %
## (Intercept) 57.600184 55.122708 60.07766
## group2 -2.332414 -5.698108 1.03328
The model can be visualised by plotting the estimated densities (see Figure 1):
lm_plot(bmod_math)
Both the estimates and confidence intervals and the density curves suggest that
there is almost no difference between the two groups. But does this really hold for
all types of students?
A tree based on this model can be computed and visualised in only two lines of
code:
tr_math <- pmtree(bmod_math, control = ctree_control(maxdepth = 2))
plot(tr_math, terminal_panel = node_pmterminal(tr_math,
plotfun = lm_plot))
The tree (see Figure 2) divides students based on the percentage of successful online
tests. These online tests were conducted biweekly throughout the semester. The
largest difference between the two exam groups is in the students who did very well
in the online tests (more than 92.3 percent correct). The tree thus gives us much
more information on the fairness of the exam than the simple linear model, which
is that it does not seem to be fair for students who did very well throughout the
semester (at this point we should state that the students self selected into the two
exam groups which might also be the reason for differences in exam performance).
Estimating personalised models is almost as simple as the stratified models:
forest_math <- pmforest(bmod_math)
pmods_math <- pmodel(forest_math)
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Figure 2: Personalised model tree for the Mathematics Exam datam.
## model parameters of first 6 students
head(pmods_math)
## (Intercept) group2
## 1 54.80224 -8.449087
## 2 40.58704 -6.119589
## 3 52.56196 -6.776434
## 4 54.58935 -8.898351
## 5 63.88527 -4.960064
## 6 41.29324 -5.991897
Dependence plots with the group effect (treatment effect) on the y-axsis and the
student characteristics on the x-axis are a good way of visualising the personalised
models and for getting knowledge about the interactions between student character-
istics and the treatment. Since the percentage of successfull online tests is measured
on a grid, a bee plot possibly shows the relationships even better than the scatter
plot (both shown in Figure 3).
dpdat_math <- cbind(pmods_math, MathExam)
ggplot(dpdat_math, aes(x = tests, y = group2)) +
geom_point(alpha = 0.2, size = 1) +
geom_smooth(fill = NA, method = "loess") +
theme(legend.position = "none") +
ylab("estmated individual\nexam group effect")
ggplot(dpdat_math, aes(x = tests, y = group2, color = tests)) +
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(b) Bee plot.
Figure 3: Dependence plot for percentage of tests successfully solved.
geom_quasirandom(alpha = 0.5, size = 1) +
theme(legend.position = "none") +
ylab("estmated individual\nexam group effect")
For the number of previous attempts to pass the exam and the gender box plots,
bee plots or a combination thereof can be used (Figure 4).
ggplot(dpdat_math, aes(x = attempt, y = group2, color = attempt)) +
geom_quasirandom(alpha = 0.5) +
theme(legend.position = "none") +
ylab("estmated individual\nexam group effect")
ggplot(dpdat_math, aes(x = gender, y = group2, color = gender)) +
geom_boxplot() +
geom_quasirandom(alpha = 0.5) +
theme(legend.position = "none") +
ylab("estmated individual\nexam group effect")
With the tools provided by the model4you package it is very simple to create un-
derstandable stratified and personalised models and compelling visualisations that
can be used to communicate theses models.
Implementation and architecture
The R package model4you is focused on ease of use and interpretability. Users can
take a simple model that they know and understand as basis and simply plug it
into pmtree() or pmforest() depending on whether they want subgroup wise or
personalised models. The basis for these functionalities is provided by the partykit
package which is a widely used R package for trees and forests [Hothorn and Zeileis,
2015, 2017]. The model4you package provides wrappers for the well implemented
and tested functions partykit::ctree() and partykit::cforest() and extends the
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(b) Gender.
Figure 4: Dependence plots for the number of previous attempts and gender.
functionalities to allow for the computation of personalised models and to improve
usability and interpretability.
The partykit package provides the basis for functionalities in other packages namely
glmertree, psychotree, betareg (all on CRAN), trtf, disttree, lagsarlmtree and palmtree
(all available on R-Forge, publishing on CRAN planned).
Quality control
All packages on CRAN undergo standard checks for compatibility with the R pack-
age ecosystem. The R package contains examples and tests. These were run and
checked on Linux 86 64 and Windows.
(2) Availability
Operating system
Should work on all operating systems that run R.
Programming language
R (version 3.1.0 or higher)
Additional system requirements
None.
Dependencies
R, partykit package (version 1.2 or higher)
List of contributors
Same as the authors: Heidi Seibold, Achim Zeileis and Torsten Hothorn
Software location:
Archive
Name: CRAN
Persistent identifier: https://cran.r-project.org/package=model4you
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Licence: GPL-2 | GPL-3
Publisher: Heidi Seibold
Version published: The version number of the software archived.
Date published: dd/mm/yy
Code repository
Name: R-forge
Persistent identifier: https://r-forge.r-project.org/projects/partykit/
Licence: GPL-2 | GPL-3
Date published: dd/mm/yy
Language
English
(3) Reuse potential
The software is intentionally written to make usage as simple as possible. The most
prominent use case are clinical trials where the assumption of an average treat-
ment effect for all patients is too strict and the efficacy of the treatment depends
on patient characteristics (e.g. gender, biomarkers, etc.). For subgroup analy-
ses (stratified treatment effects) model-based trees (pmtree()) can be used; For
personalised treatment effects model-based forests (pmforest()) provide a way of
estimating similarity between patients and using this similarity measure to esti-
mate personalised models (pmodel()). The target audience are people who deal
with heterogeneous treatment effects, such as medical researchers, pharmaceutical
companies or analysts in marketing (A-B testing). In general the software is use-
ful to researchers dealing with scenarios where two exposures are compared and
responses of subjects possibly depend on other variables.
We encourage users to use the party tag on Stackoverflow (http://stackoverflow.
com/questions/tagged/party) in case of questions or problems.
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